Innovative approaches to aphasia rehabilitation: a review on efficacy, safety, and controversies.

Chiara Picano 1, Agnese Quadrini 2, Francesca Pisano 3 and Paola Marangolo 1,3, *

1 University La Sapienza, Rome, Italy; chiarapicano1@gmail.com
2 IRCCS Santa Lucia Foundation, Rome, Italy; agnese.quadrini@gmail.com
3 Department of Humanities Studies, University Federico II, Naples, Italy; francescapisano00@virgilio.it

* Correspondence: paola.marangolo@gmail.com

Abstract: Aphasia is one of the most socially disabling post-stroke deficits. Although traditional therapies have been shown to induce adequate clinical improvement, aphasic symptoms often persist. Therefore, new rehabilitation techniques which act as a substitute or as an adjunct to traditional approaches are urgently needed.

The present review provides an overview of the efficacy and safety of the most innovative approaches which have been proposed over the last twenty years. First, we examined the effectiveness of the pharmacological approach, principally used as an adjunct to language therapy, reporting the mechanism of action of each single drug for the recovery of aphasia. Results are conflicting but promising. Secondly, we discussed the application of Virtual Reality (VR) which has been proved to be useful since it potentiates the ecological validity of the language therapy by using virtual contexts which simulate real-life everyday contexts.

Finally, we focused on the use of Transcranial Direct Current Stimulation (tDCS), both discussing its applications at the cortical level and highlighting a new perspective, which considers the possibility to extend the use of tDCS over the motor regions. Although the review reveals an extraordinary variability among the different studies, substantial agreement has been reached on some general principles, such as the necessity to consider tDCS only as an adjunct to traditional language therapy.

Keywords: Post-stroke aphasia; aphasia rehabilitation; pharmacological approach; virtual reality; transcranial direct current stimulation (tDCS)

1. Introduction

Aphasia is a common disabling neuropsychological disorder which occurs in about one-third of people suffering from left-cerebral artery stroke [1,2]. It impairs the person’s ability to process language with heterogeneous symptoms varying in terms of severity and degree of involvement across the different linguistic modalities, including the expression and comprehension of language, reading and writing [3]. Variation in the severity of expressive impairments, for example, may range from the patient’s occasional inability to find the correct word to telegraphic and very reduced speech output [4]. Aphasia can be considered one of the most socially disabling syndrome after stroke. Indeed, the inability to process language determines a dramatic loss of autonomy and compromises a range of life experiences including the possibility to exchange social relationships [5].

After an initial spontaneous recovery, most notably during the first 2–3 months following stroke onset, language improvement can occur in response to behavioral training also in the chronic phase [6].
The recent progress in neurorehabilitation, which takes into account the mechanisms underlying cerebral reorganization [7-9], has suggested that intensive language training (several hours per week) seems to be a crucial predictor for positive language outcomes [10].

Unfortunately, given the limited economic resources of the healthy system and the costs to have access to private health care services, most of the persons with aphasia (PWA) cannot receive the recommended amount of training estimated [10,11]. As a consequence, conventional speech-language therapies do not always result efficacious and many patients are left with some degree of language deficits [12,13].

Therefore, new rehabilitation techniques which act as a substitute or as an adjunct to traditional approaches are urgently needed in order to maximize the language recovery process. In this context, new approaches which increase treatment effectiveness, by either improving the total amount of learning achieved or by speeding up the learning process, have been proposed [14]. In particular, to date, three approaches resulted promising for positive language outcomes: the pharmacological approach, Virtual Reality (VR), and Transcranial direct current stimulation (tDCS).

With regard to the first approach, despite the recently waned interest for pharmacotherapy in aphasia, it has been demonstrated that some types of drugs, acting on neurotransmitter activity, promote adaptive neuroplasticity and network remodeling [15]. Indeed, they seem to rebalance the altered neurotransmitters, thus, improving cognitive performance [16,17].

With regard to Virtual Reality, the hypothesis has been advanced that, the use of virtual contexts promotes the ecological validity of language therapy which seems to be a key predictor for language recovery [12].

With regard to tDCS, there is substantial agreement on its use as an adjunct to language therapy [18]. Indeed, to date, the application of tDCS has been extended in domains other than the treatment of word finding difficulties [19-23], such as the recovery of articulatory deficits [24-26] and speech production [27-30].

The purpose of the present review is to gain an understanding of the existing new approaches for aphasia rehabilitation and to provide a critical overview of the state of the art.

2. Pharmacological Approach

In post-stroke aphasia, and all stroke cases, there is an acute stage followed by a period of spontaneous recovery in which many symptoms can regress. Immediately after the cerebrovascular event, a series of metabolic neural reorganizations occurs [31]. These metabolic changes include ischemic penumbra, a dysfunctional cerebral area surrounding the infarct due to reduced blood flow [32]; this area can be saved because its neurons could remain alive for some time. Another event is the diaschisis, which consists of neurophysiological changes (with inhibitory or excitatory effects) directly caused by a focal injury in anatomically intact areas distant from the lesion [33]. Lastly, during this period of spontaneous recovery, also phenomena of brain plasticity take place [34].

The interest in the pharmacological treatment for post-stroke aphasia arises from the hypothesis that drugs could act on those post-stroke mechanisms, thus, promoting language recovery [35]. Indeed, one of the mechanisms by which stroke can cause aphasia concerns the damage of the neurotransmitter pathways [36,37].

In the next paragraph, we present the main drugs used as an adjunctive or substitutive treatment for aphasia. All the published studies and details on their methodological aspects are summarized in Table 1.
# Table 1. Pharmacological studies in aphasia recovery.

Abbreviations: *RCT: randomized controlled trial; SC: single case; CS: case series; OLT: Open-label trial; CT: Controlled-Trial not randomized; ERP: event-related potentials.

| Articles* | Type of Drug and dose | Study design | Patients | Task | Trial duration | Side Effects | Effects |
|-----------|-----------------------|--------------|----------|------|----------------|--------------|---------|
| Güngör et al., 2011 [38] | Piracetam (4800 mg/day) | RCT | 30 acute* | No | 6 months | Gastrointestinal irritability, nausea, vomiting, anxiety, irritability, agitation, seizures | Improvement in auditory comprehension |
| Kessler et al., 2000 [39] | Piracetam (4800 mg/day) | RCT | 24 acute | Intensive language therapy; occupational therapy | 6 weeks | Not reported | Improvement in spontaneous speech |
| Huber et al., 1997 [40] | Piracetam (4800 mg/day) | RCT | 50 acute | Intensive language therapy (symptom-specific training) | 6 weeks | No | Improvement in written language |
| Enderby et al., 1994 [41] | Piracetam (4800 mg/day) | RCT | 137 acute | Speech therapy (unspecified tasks) | 12 weeks | Sleep disturbances, vertigo, tiredness | Improvement in repetition and written language |
| Dávila et al., 2020 [42] | Donepezil (up to 5 mg/day) | SC | 1 chronic | Drug alone; Intensive Naming Therapy (INT) | 32 weeks | No | Drug alone: improvement in fluency and spontaneous speech. Drug + INT: improvement in naming |
| Berthier et al., 2017 [43] | Donepezil (up to 10 mg/day) | SC | 1 chronic | Drug alone; Audiovisual repetition-imitation therapy | 4 months | Not reported | Improvement in speech production and phrase repetition (both drug alone and drug + audiovisual repetition-imitation therapy) |
| Woodhead et al., 2017 [44] | Donepezil (up to 10 mg/day) | RCT | 20 chronic | Phonological training ("Farobics") software | 25 weeks | Insomnia, headaches, dizziness, muscle cramps | Worsening in comprehension |
| Authors, Year | Treatment | Outcome | Design | Duration | Side Effects | Outcomes |
|--------------|-----------|---------|--------|---------|-------------|---------|
| Yoon et al., 2015 | Donepezil (up to 10 mg/day) | 1 sub-acute/chronic (two infarction: 8 years before and 4 months before) | SC | No | 12 weeks | Not reported |
| | | | | | | Improvement in comprehension and spontaneous speech |
| Berthier et al., 2006 | Donepezil (up to 10 mg/day) | 26 chronic | RCT | Speech-Language Therapy (SLT) (unspecified tasks) | 20 weeks | Irritability, insomnia, tiredness |
| | | | | | Improvement in picture naming |
| Berthier et al., 2003 | Donepezil (up to 10 mg/day) | 11 chronic | OLT | Speech-Language Therapy (SLT) (unspecified tasks) | 20 weeks | Irritability, increased sexual drive |
| | | | | | Improvement in phonemic discrimination of no words, repetition, word-picture matching |
| Hong et al., 2012 | Galantamine (up to 16 mg/day) | 45 chronic | OLT | Speech-Language Therapy (SLT) (unspecified tasks) | 20 weeks | No |
| | | | | | Improvement in spontaneous speech, comprehension, and naming |
| Barbancho et al., 2015 | Memantine (10 mg/day) | 28 chronic | RCT | Drug alone; Constraint-Induced Aphasia Therapy (CIAT) | 20 weeks | No |
| | | | | | General improvement in the severity of aphasia (in both conditions) |
| | | | | | Improvement in spontaneous speech, comprehension, naming, and everyday communication |
| Breitenstein et al., 2015 | L-dopa (100 mg/day) | 20 chronic | RCT | Conversational training; naming exercises; | 6 months | Not reported |
| | | | | | No significant effect |
| Leemanni et al., 2011 | L-dopa (100 mg/day) | 17 sub-acute | RCT | Computer-Assisted Therapy (CAT) | 2 weeks | Not reported |
| | | | | | No significant effect |
| Seniów et al., 2009 | L-dopa (100 mg/day) | 39 acute/sub-acute (2 to 8 weeks post-onset) | RCT | Speech-Language Therapy (SLT) (unspecified tasks) | 3 weeks | No |
| | | | | | Improvement in verbal fluency and repetition |
| Ashly et al., 2006 | Bromocriptine (up to 10 mg/day) | 38 acute | RCT | No | 4 months | No |
| | | | | | No significant effect |
| Rayner et al., 2001 | Bromocriptine (up to 20 mg/day) | 1 sub-acute | SC | No | 2 months | Not reported |
| | | | | | Improvement in verbal fluency |
| Study            | Treatment                          | Design   | Duration | Outcome                                                                 |
|------------------|------------------------------------|----------|----------|-------------------------------------------------------------------------|
| Gold et al., 2000 | Bromocriptine (up to 15 mg/day)    | OLT      | 4 sub-acute | No                                                                 |
|                  |                                    |          |          | 8 weeks                                                                 |
| Bragoni et al., 2000 | Bromocriptine (up to 30 mg/day) + domperidon | CT       | 11 chronic | Drug alone; Speech Therapy (ST) (unspecified tasks)                     |
|                  |                                    |          |          | 4 months                                                                 |
| Sabe et al., 1995 | Bromocriptine (up to 60 mg/day)    | RCT      | 7 chronic | No                                                                      |
|                  |                                    |          |          | 6 weeks                                                                 |
| Gupta & Mloch, 1992 | Bromocriptine (up to 30 mg/day)    | OLT      | 2 chronic | No                                                                      |
|                  |                                    |          |          | 3 months                                                                 |
| Keser et al., 2017 | d-Amphetamine (10 mg, two doses)   | RCT      | 10 chronic | Melodic Intonation Therapy (MIT) by 10 washout days                     |
|                  |                                    |          |          | Mild insomnia                                                            |
| Walker-Batson et al., 2001 | d-Amphetamine (10 mg/day) | SC       | 1 (stroke stage not reported) | Speech therapy (unspecified tasks)                                      |
|                  |                                    |          |          | 3 weeks                                                                  |
| Whiting et al., 2007 | d-Amphetamine (5 mg/day)           | CT       | 2 chronic | Computer-based therapy                                                  |
|                  |                                    |          |          | 1 month                                                                  |
| Stefanatos et al., 2006 | d-Amphetamine (20 mg, single dose) | CT       | 10 sub-acute | No                                                                       |
|                  |                                    |          |          | 1 day                                                                    |
| Walker-Batson et al., 2001 | d-Amphetamine (10 mg/day) | RCT      | 21 acute | Speech-Language Therapy (SLT) (individualized, based on traditional stimulation/facilitation model) |
|                  |                                    |          |          | 6 months                                                                 |

**Table Notes:**
- OLT: Oral Levodopa Therapy
- CT: Computer-based Therapy
- SC: Speech Therapy
- RCT: Randomized Controlled Trial
- No significant effect
- Improvement in auditory attention
| Authors            | Treatment/Drug                           | Dosage               | Type  | Duration | Side Effects | Outcome                      |
|--------------------|------------------------------------------|----------------------|-------|----------|--------------|------------------------------|
| McNeil et al., 1997 [65] | Selegiline (up to 20 mg/day)            | CT                  | 2 chronic | 21 days | Not reported | No significant effect       |
| Walker-Batson et al., 1992 [66] | d-Amphetamine (up to 15 mg/day)          | OLT                 | 6 acute | 3 months | Mild insomnia | No significant effect       |
| Walker-Batson et al., 1991 [67] | d-Amphetamine (10 mg/day)                | SC                  | 1 acute | 11 months | Not reported | General improvement in aphasia severity, in particular in verbal fluency |

* Acute (< four weeks post-onset); Sub-Acute (> four weeks post-onset); Chronic (> one year post-onset)
2.1 Drugs acting on GABA, acetylcholine, and glutamate systems: piracetam, donepezil, galantamine, and memantine

Piracetam is a derivative of GABA (γ-aminobutyric acid), but its mechanism of action appears to be unrelated to the properties of this neurotransmitter.

Several well-designed trials have investigated the combined effect of piracetam with language treatment in post-stroke aphasia [39-41] administering a dose of 4800 mg/day in acute post-stroke patients. In all studies, significant improvements were found in the piracetam group compared to the placebo group. In particular, compared to baseline, better performance was observed in written language [40-41], repetition [41] and spontaneous speech [39].

Differently from previous studies, Güngör et al. [38] investigated the effect of piracetam as a substitutive treatment of speech therapy. Fifteen patients received oral piracetam as a daily dose of 4.8 g for 24 weeks, while fifteen patients received a placebo with the same dose. After the treatment, a significant improvement in auditory comprehension was reported which did not persist at six months after the end of the therapy.

The exact mode of action of the piracetam is still unknown but there is increasing evidence that its underlying effect is to reestablish cell membrane fluidity. As a consequence, piracetam could have a neuroprotective action, it may restore neurotransmission and enhance neuroplasticity [68]. Moreover, the hypothesis has been advanced that piracetam facilitates the transcallosal transfer of information from one hemisphere to the other, promoting relearning of degraded linguistic knowledge and learning of compensatory strategies [32].

In summary, piracetam could act as a potential drug for language recovery in aphasia but, to date, the number of studies is too small in order to reach definite conclusions on its real therapeutic efficacy.

Donepezil is a reversible acetylcholinesterase inhibitor [69]. Acetylcholinesterase is an enzyme that catalyzes the breakdown of acetylcholine, so the drug, increasing the presence of this neurotransmitter in the synaptic cleft, enhances its action [70]. Cholinergic pathways are vulnerable to vascular damage and stroke could interrupt cholinergic projections in cortical sites necessary for language processing [71].

Studies about donepezil therapy in aphasia have reported contrasting data. In three studies, Berthier et al. [43,46,47] have shown a positive effect of the drug in repetition, picture-naming, and speech production with mild adverse effects (irritability, increased sexual drive, insomnia, headaches, dizziness, muscle cramps). Dávila et al. [42] found an improvement in fluency, spontaneous speech, naming and phrase repetition but, in this case, no side effects were found. In this last study, in our opinion, the absence of side effects was probably due to the young age of the participant (9 years old) and the fact that the dosage of the drug was really small (5 mg/day).

The patient of Yoon et al. [45] improved in spontaneous speech and comprehension, while, in Woodhead et al.’s study [44], worse comprehension in the drug condition compared to placebo was, unexpectedly, found. The hypothesis advanced in this last study was that cognitive-enhancement drugs can have opposite effects on cognitive tasks, as an inverted U-shaped relationship: hence, if acetylcholine stimulation is already high in the auditory cortex, a further increase through donepezil might worsen the patient’s performance [72].

It is interesting to note that in all of these studies the patients had chronic aphasia, so donepezil does not seem to act on spontaneous recovery mechanisms which occur in the acute stage. It has been suggested that donepezil plays probably a role in language recovery enhancing the effect of speech therapy: indeed, an increase of cholinergic transmission into the cortex could boost attention and learning, facilitating the encoding of verbal stimuli and filtering of irrelevant ones [36,73].

Galantamine, like donepezil, is a reversible acetylcholinesterase inhibitor that modulates multiple subtypes of nicotinic acetylcholine receptors [48]. It is currently being researched for the
treatment of Alzheimer’s disease [74] and, in some studies, it was also administered in chronic aphasia.

Hong et al. [48] conducted an open-label trial on 45 chronic aphasic patients, administering galantamine without any adjunctive therapy, and they observed a significant improvement in spontaneous speech, comprehension, and naming.

Galantamine augments NMDA-evoked currents in rat cortical neurons and potentiates the activity of NMDA receptors is considered partially responsible for the improvement of cognition, learning and memory in Alzheimer’s patients [75]; however, only one trial is not enough to establish its efficacy in post-stroke aphasia.

Memantine is an uncompetitive NMDA receptor antagonist, thus, it reduces neurotransmitter glutamate activity. Two double-blind placebo-controlled studies [49,50] have investigated the effects of memantine on chronic post-stroke aphasia both considering the drug as adjunctive treatment to constraint-induced aphasia therapy (CIAT).

Barbancho et al. [49] observed a general increase in language functions. Berthier et al. [50] found a significant improvement in spontaneous speech, comprehension, naming and everyday communication. Interestingly, these beneficial effects of memantine persisted at the 6-months follow-up evaluation.

The effect of this drug is peculiar because other NMDA receptor antagonists (like ketamine) have serious negative effects [76]. The hypothesis is that the memantine-specific mechanism of action on NMDA receptors could provide both neuroprotection and reverse deficits in learning and memory [77]. It seems that it can augment synaptic plasticity and long-term potentiation in spared networks through enhancing activity-dependent learning mechanisms in language-related brain regions [77].

Memantine has already the authorization to be used in Alzheimer’s disease because these patients manifest an over activation of glutamate receptors, in particular, the NMDA ones [77]; but further studies to confirm its therapeutic effect also in post-stroke aphasia are needed.

2.2 Drugs acting on monoaminergic systems: levodopa, bromocriptine, and amphetamines

Several studies investigated the therapeutic potential of monoamine agonists, especially dopamine, in aphasia recovery. The rationale is broad: dopamine pathways are present in many cerebral areas involved in language processing and damage into these areas could cause aphasic symptoms [70].

The second explanation concerns LTP (Long Term Potentiation) mechanisms, in particular, the role of NMDA receptors over these mechanisms. In fact, NMDA-dependent LTPs are involved in different forms of memory [70]. Nevertheless, for long-lasting effects, neither NMDA receptors alone nor combined with other glutamatergic agonists are sufficient and an adjunctive mechanism is needed to exert the intended effect [78,79]. This additional mechanism could be related to monoamines’ action; indeed, two studies have already shown that depletion of serotonin or catecholamine could modulate LTP mechanisms in the dentate gyrus in rats [80,81]. Thus, in order to maintain long-lasting therapeutic effects for aphasia recovery, an increase of monoamines’ action might be the responsible factor.

Levodopa (L-dopa) is a dopamine precursor. Dopamine modulates attentional processes, working memory, long-term potentiation, neuronal growth and it improves word learning in healthy humans [82-86]. Only three studies investigated the effect of this drug on aphasia.

Seniów et al. [53] administered L-dopa as adjunctive treatment to speech-language therapy (SLT) in acute aphasic patients and found an improvement in verbal fluency and repetition compared to the placebo group. Leemann et al. [52] and Breitenstein et al. [51], in contrast, found no significant differences in the L-dopa-group combined with high-intensity language training compared with the placebo-group (only high-intensity language training).

According to Breitenstein and colleagues [51], “the negative effect could be due to a behavioral “ceiling” effect induced by the high intensity training (four hours per day), touching the physiological plasticity limit”. This hypothesis is supported by prior findings on significant L-dopa effects for
language recovery combined with a daily intensive treatment of forty-five minutes in subacute stroke patients with circumscribed anterior lesions [53] but not in subacute stroke patients undergoing a speech-language therapy regime of two hours per day [52].

Bromocriptine is a dopamine agonist which stimulates D2 dopamine receptors non-adenyl cyclase-linked [87]. Based on the effects of dopamine, various trials investigated the effect of this drug on post-stroke aphasia as a substitute to traditional language therapy.

Gupta & Mcloch [59] found an improvement in mean length utterance, verbal fluency, and naming; Raymer et al. [55] reported significant improvement in verbal fluency and Gold et al. [56] in word retrieval. Sabe et al. [58] and Ashtary et al. [54], conversely, did not find any effects. Bragoni et al. [57] investigated the efficacy of bromocriptine alone and as an adjunct to traditional therapy and found a significant improvement in reading comprehension and verbal latency (the time delay in starting to declare words expressed in seconds) in both experimental conditions. When the drug was combined with language treatment, a significant improvement in repetition was also found. However, in this last study, the patients reported several severe adverse effects: epileptic seizures, atrial flutter, atrial fibrillation, visual hallucinations, mild nausea and a syncopal episode. In agreement with de Boissezon et al. [88], we believe that it is not possible to conclude on any effective influence of bromocriptine on aphasia symptoms and the encouraging reports seem rather anecdotal.

The term “amphetamines” generally refers to amphetamine proper and all its relatives, like MDMA (or ecstasy) methamphetamine, dextro-amphetamine [89]. The major mechanism of action of these substances is to block and/or reverse dopamine, norepinephrine, and serotonin reuptake transporters, causing an increase of these neurotransmitters in the synaptic cleft [90,91]. The result of this action is a psychoactive effect; indeed, they can increase arousal, vigilance, wakefulness, and attention [92]. For this reason, amphetamines are currently the most widely misused stimulants [93]. Like other abused drugs, amphetamines cause tolerance and psychological addiction and cognitive impairments could arise in habitual users [94-96]. Nevertheless, to date, they are already approved for the treatment of Attentional Deficit Hyperactivity Disorders (ADHD) and narcolepsy [90]. Their possible therapeutic effects are also currently studied for many disturbances like eating disorders, multiple sclerosis, and schizophrenia [90,97], as well as motor recovery [98] and aphasia.

Walker-Batson and her research team [67] published the first single case study in an acute patient on the use of amphetamines (dextro-amphetamine) in aphasia as an adjunctive treatment to Speech-Language Therapy (contrastive stress drills coupled with traditional speaking, reading, and auditory comprehension tasks). A significant improvement in different aspects of language was found and, in particular, in verbal fluency. Some years later, the same authors published an open-label pilot study [66] but the results were not significant. After these preliminary studies, other trials reported contrasting results in chronic post-stroke aphasia. Whiting et al. [62] and Spiegel and Alexander [61] found some general but non-significant improvements, administering dextro-amphetamine adjunctively to traditional speech therapy [61] and computer-based speech therapy [62]. McNeil et al. [65] did not obtain significant effects even with the administration of selegiline (a derivative of methamphetamine).

Interestingly, very recently, Keser et al. [60] investigated the effect of dextro-amphetamine combined with tDCS and Melodic Intonation Therapy (MIT). Ten subjects with chronic nonfluent aphasia underwent two experiments where they received dextroamphetamine or placebo along with tDCS and MIT over two days, separated by a ten-days washout period. The authors observed a general significant improvement in aphasia severity when the different therapeutic approaches were combined together and no side effects, demonstrating that triple combination therapy is safe. Several years after the first open-label reports, Walker-Batson et al. [64] published a randomized, double-blind, placebo-controlled trial and found a significant and positive effect of dextro-amphetamine in acute post-stroke aphasia. Similar results were found by Stefanatos et al. [63]. It is interesting to note that, in this last study, the drug treatment was substitutive to traditional therapy and it was particularly effective also in auditory attention. In all of these trials, no severe adverse effects were observed, only episodes of mild insomnia have been reported [60,66].
D-amphetamine seems to be more effective during the acute stage than in the chronic stage, but only a few studies have investigated the effects of this drug in patients with chronic post-stroke aphasia. D-amphetamine plays a role in synaptogenesis; thus, it seems that the treatment with d-amphetamine, combined with a language task, can selectively regulate the growth of neurites, in the brain circuits underlying the behavioral function tested, despite the loss of the original pathways [99]. However, as for the other pharmacological approaches, further clinical trials are required in order to clearly understand its effectiveness.

2.3 Conclusions

In this section, we examined the current state of evidence regarding the major drugs used for aphasia treatment. In most studies, the drug therapy was administered in combination with conventional language protocols; bromocriptine is the only drug that has been studied primarily as a substitute for speech therapy but there is no evidence of positive effects and possible side effects of this drug are alarming [57,58].

In general, the main problem of all of these studies is the lack of a sufficient number of double-blind, placebo-controlled trials with large sample size. Another problem lies on the fact that our knowledge regarding the precise therapeutic mechanisms of action of each drug is still insufficient, together with their side effects and efficacy over a long period of use.

Thus, further studies on the above reported drugs are needed in order to reach definitive conclusions. Moreover, it would be also interesting to include some studies on the role of other drugs in post-stroke aphasia, such as Fluoxetine, Niacin, Inosine, and Citicoline, which have already been used in post-stroke patients in order to improve motor recovery but not in post-stroke aphasia [100].

3. Virtual Reality Approach

Digital therapeutics is a newly emerging concept of therapeutic approach in the healthcare system which includes smartphones, personal digital assistants, computer programs, tablets, and virtual reality (VR) [101]. Indeed, the use of digital devices could facilitate high-intensity programs and help patients maintaining their improvements [101]. This is especially true for tablet or computer self-administered therapies delivering several language exercises on words and sentences listening, reading, and writing and also for speech fluency [102-106]. Home practice programs could also solve the problem of travelling for patients who live far away from rehabilitation centers, especially those who have also motor impairments [107].

To date, there is a growing body of studies on the use of these technologies, and, in particular, VR, for the treatment of post-stroke impairments [108], such as aphasia.

Development of VR applications for the rehabilitation of aphasia is still at its early stage ([109-112]; see for a review [101]). This involves a computer-generated simulation of 3D environments with which the user can experience a semi-immersive interaction that may encourage language practice in real context communication settings. Typically, an individual entering a virtual environment feels a part of this world and she/he has the opportunity to interact with it almost as she/he would do in the real world. Accordingly, the latest Cochrane review on speech and language therapy following stroke concluded that therapy should enhance functional communication in ecological contexts [12]. Indeed, a common observation regarding PWA is that they can communicate much more than their linguistic abilities would suggest. Therefore, the hypothesis has been advanced that a more ecological approach aimed at restoring the patient’s ability to communicate in different daily contexts, such as VR, would be proved useful in aphasia rehabilitation [23,113-115].

Another important advantage of VR is that the inclusion of a virtual therapist allows to communicate with the patient in an asynchronous mode without requiring the physical presence of a clinician [116,117]. This would further reduce the costs of the therapy and, thus, promote intensive treatment.
In the next paragraph, we report a presentation of the VR studies published until now for the treatment of aphasia. All the reported studies and details on their methodological aspects are summarized in Table 2.
Table 2. Virtual Reality studies in aphasia recovery. Abbreviation: *RCT: randomized controlled trial; CS: case series; RGSa: Rehabilitation Gaming System for aphasia Interaction; VRRS-Tablet: Virtual Reality Rehabilitation System; RGS Rehabilitation Gaming System; VR: virtual reality.

| Articles* | Study design | Patients | Task | Technology | Trial duration | Effects |
|-----------|--------------|----------|------|------------|----------------|---------|
| Giachero et al., 2020 [118] | RTC | 36 chronic* | Conversational Training Therapy (CTT) | VR (NeuroVR 2.0) | 6 months | VR improved oral comprehension, repetition, written language, self-esteem, and emotional state |
| Marshall et al., 2020 [119] | RTC | 34 aphasics | Group Therapy | VR (EVA Park) | 6 months | No significant improvement in wellbeing, communicative success |
| Grechuta et al., 2019 [109] | RTC | 17 chronic | Intensive Language-Action Therapy (ILAT) | RGSa | 8 weeks | Improvement in speech production, auditory comprehension, communicative effectiveness in everyday life, and lexical access |
| Maresca et al., 2019 [120] | RTC | 30 subacute | Naming, composition, writing and rewriting | VRRS-Tablet | 6 months | VRRS-Tablet Significant improved comprehension, repetition, reading, calculation, competence, adaptability, and self-esteem |
| Study                        | Intervention Type | Time Duration | Outcome | Notes |
|------------------------------|-------------------|---------------|---------|-------|
| Marshall et al., 2018 [121] | CS                | 2 chronic     | VR      | 5 weeks | VR improved noun retrieval |
| Carragher et al., 2018 [122]| CS                | 3 chronic     | VR      | 5 weeks | VR improved storytelling  |
| Grechuta et al., 2017 [123] | Longitudinal trial| 4 chronic     | RGS     | 8 weeks | RGS improved word retrieval and verb execution |
| Marshall et al., 2016 [112] | quasi-RTC         | 20 chronic    | VR      | 5 weeks | VR improved functional communication |

* Acute (< four weeks post-onset); Sub-Acute (> four weeks post-onset); Chronic (> one year post-onset).
Marshall et al. [112] designed a semi-immersive virtual world called EVA Park, a virtual island with houses, a cafe, a restaurant, a health center, a hair salon, a tropical bar, and a disco. Users can visit the places, interact with the several objects available, and communicate with other users with a personalized avatar. The quasi-randomized controlled design compared a group that received immediate EVA Park intervention with a waitlist control group. The content of the intervention was largely driven by participants that set at least three context-bound goals such as ordering food in a restaurant or making a doctor’s appointment. Outcomes showed significant improvement in functional communication, but no significant effects in verbal fluency, word-finding in conversation, narrative, and communication confidence.

Marshall et al. [121] reported another EVA-Park-based intervention in two single cases. Treatment consisted of noun retrieval therapy for the first patient and Verb Network Strengthening Treatment for the second one, conducted remotely in EVA Park delivered over five weeks. Both patients showed excellent compliance and positive views about EVA-Park-experience and they had a significant increase in naming after the end of therapy which in one case was not maintained at five-weeks follow-up.

Very recently, Marshall et al. [119] published a randomized controlled design in which a group therapy was virtually implemented in EVA Park, with patients, volunteers, and coordinators present in the VR environments. Two intervention groups were randomized to an immediate therapy condition and two were randomized to a delayed condition. The comparison of scores was made when the immediate condition had received the intervention, and the delayed group had not yet undergone the treatment. The study aimed to investigate whether it is feasible to deliver group social support to people with aphasia via a multi-user, VR platform. It also explored the indicative effects of intervention and the costs. Possible improvements in wellbeing and communicative success were also measured. No significant changes were found on any of the outcome measures, although the study was not powered to detect these. The results suggest the need to implement the study with a larger trail of remote group support, using VR.

A pilot study explored the remote delivery of storytelling intervention in EVA Park on three patients with chronic aphasia [122]. Participants practiced with a therapist to generate a story based on video stimuli and then, met a volunteer who was unfamiliar with the story to tell it in their own words. Following the intervention, two participants showed an increase in the number of content words produced in storytelling.

Grechuta and collaborators published a pilot study prior [123] to a randomized controlled trial [109]. In both studies, they investigated a new VR intervention with motion tracking. Patients interacted with the system by performing horizontal arm movements over a table surface. These movements were tracked in real-time and mapped onto avatars’ upper limbs, allowing the interaction with virtual objects. This method was based on the assumption that motor planning and control circuits seem to be also involved in the comprehension and perception of language; in particular, during speech perception, specific motor circuits are recruited that reflect phonetic features of the speech sounds encountered [124]. The paradigm involves two patients interacting with each other by requesting objects, placing their hand on top of them, and verbally requests them. In the pilot study [123], a silent video representing the correct pronunciation of the target word aided the verbal request and the results showed that these silent visuomotor cues facilitated word retrieval and verbal execution. In the second study [109], the authors compared the effect of this training with Intensive Language-Action Therapy (ILAT) and they found that both groups improved in speech production, auditory comprehension, communicative effectiveness in everyday life, and lexical access, but only the experimental group maintained the improvements at sixteen-weeks-follow-up.

Maresca et al. [120] investigated the effect of a VR-based intervention using tablets compared to traditional therapy (the same exercises delivered by tablet but using paper-pencil tools). The training includes exercises in which the patient interacts with objects and virtual scenarios through a touch screen. The exercises concerned tasks of naming, composition, writing, and rewriting suggested by acoustic, textual, or visual items. Results showed that the experimental group improved in all investigated tasks except in writing, while the control group improved only in comprehension, depression, and quality of life.
Very recently, Giachero et al. [118] explored the effectiveness of conversational therapy paired with semi-immersive VR-experience compared to therapy without VR support in two different groups of chronic aphasia patients. The effectiveness of the treatment was evaluated not only on language skills but also through scales for measuring different psychosocial aspects. Participants were asked to explore different virtual everyday scenarios which included cognitive exercises with language, memory, and attentional tasks. The interaction among patients was mediated by a speech therapist who operated in the VR scenario through the use of a personal computer. After the treatment, no significant differences in the different measures were present between the two groups. However, the amount of improvement in the different areas was distributed over far more cognitive and psychological aspects in the VR group than in the control group. Indeed, the within-group comparisons showed a significant enhancement in different language tasks (i.e., oral comprehension, repetition, and written language) only in the VR group. Interestingly, after the treatment, significant gains were also found, in the VR group in different psychological dimensions such as in their self-esteem and emotional and mood state.

3.1 Conclusion

From the studies reported above, it seems likely that the use of VR, although it is still in its infancy, is promising. First, in the case of self-administration treatments delivered at home, this would engage the patient for several hours a day, thus, partly resolving depressive and social isolation feelings which are often observed in PWA. Indeed, the possibility for the patients to practice on their own and to take care of themself would enhance their responsibility, their self-esteem, self-efficacy, and independence. This would also guarantee the possibility to undergo an intensive treatment program which is one of the key predictors in aphasia rehabilitation in order to obtain the best language outcome.

Secondly, interventions would occur in virtual everyday contexts, thus enhancing the ecological validity of the treatment protocols [12,118]. Finally, the impact of VR for language recovery, as already pointed out [109,123], is in line with a recent perspective which considers the language faculty as represented in a multimodal dimension where word semantics contain sensorimotor properties, which rely on areas not previously hypothesized by the traditional approach, such as the sensorimotor network [118,125]. Within this view, these sensorimotor properties are more easily enhanced in a VR environment than in an usual language therapy settings.

4. Transcranial direct current stimulation (tDCS) approach

Transcranial Direct Current Stimulation (tDCS) is a non-invasive technique which, in these last years, has been considered as a new potential adjunctive therapy for neurological disorders [126,127]. Indeed, tDCS induces a weak electrical current (1-2 mA) through a pair of surface electrodes applied over the scalp, which modulates cortical excitability over a period of time (usually 20 to 30 minutes), thus, potentiating the effects of the treatment [128,129]. It has been shown that the electrical current employed in tDCS acts on the resting membrane potentials increasing or decreasing the probability that neural firings are triggered; anodal stimulation induces depolarization of the neuronal membrane, thus, increasing the spontaneous neuronal firing rate, whereas cathodal stimulation leads to neuronal hyperpolarization and inhibition [129,130]. These effects may last for minutes to hours depending on the intensity, polarity, and duration of stimulation [129]. In all the experimental protocols, two different stimulation conditions are usually employed: a real condition and a placebo condition. During the real condition, the anode or cathode are applied over the target area to explore respective excitatory or inhibitory effects. Conversely, during the placebo condition, called sham condition, the stimulator is turned-off after few seconds. The comparison of these two stimulation conditions is necessary in order to ensure that the patient’s behavioral changes are specifically attributable to stimulation [18]. A growing body of evidence has already suggested that tDCS
provides a supplementary treatment approach for language deficits in patients with chronic stroke-induced aphasia [4,18].

A PubMed search on "tDCS and aphasia" produced 39 randomized-controlled trials in post-stroke chronic aphasia. From this research, we excluded five studies on acute patients [131-135] and six single-case studies [136-141].

From these selected studies, an extreme variability emerged with respect to electrodes location, current density, number of tDCS sessions, length of follow-ups and the language protocols and outcome measures applied. Thus, this methodological heterogeneity makes it difficult to establish universal principles on the use of tDCS in aphasia. However, we will report some general assumptions on which there is substantial agreement in the literature.

In the next paragraph, a brief overview of the tDCS studies published until now for the treatment of aphasia is reported. All the reported studies and details on their methodological aspects are summarized in Table 3.
Table 3. Transcranial direct current stimulation studies in aphasia recovery. Abbreviation: * L left; R: right; IFG: inferior frontal gyrus; ST: superior temporal; M1: motor cortex; PPR: posterior perisylvian region; DLPFC: dorsolateral-prefrontal cortex.

| Articles                  | Patients Description | Task                              | tDCS vs sham | Target (areas) | tDCS stimulation parameters | Generaliz. | Follow up | Effects                        |
|---------------------------|----------------------|-----------------------------------|--------------|----------------|----------------------------|------------|-----------|--------------------------------|
| Guillouët et al., 2020    | 14 aphasics (7 non-fluent, 4 fluent mixed), but 10 patients completed the study | Personalized speech and language therapy | No           | Bihemispheric | 2 mA, 20 min | No         | No        | no improvement in spontaneous speech |
|                          |                      |                                   |              | Anode: L IFG  | 2-5 sessions a week for 3 weeks |            |           |                                 |
|                          |                      |                                   |              | Cathode: R IFG|                                  |            |           |                                 |
| Marangolo et al., 2020    | 16 aphasics          | Verb naming                       | Yes          | Anode: 10th thoracic vertebra      | 2 mA, 20 min | Yes       | No        | improvement in verb naming and significant changes in functional connectivity |
|                          |                      |                                   |              | Cathode: R IFG| 5 sessions                       |            |           |                                 |
| Fiori et al., 2019        | 2 groups of 10 non-fluent aphasics | Verb naming                       | Yes, only after cathodal stimulation at 2mA | Cathode: R IFG | 1mA, 20 min | Not investigated | Yes, at 1 week | improvement in verb recovery |
|                          |                      |                                   |              | Anode: L M1 | 2mA, 20 min |            |           |                                 |
|                          |                      |                                   |              |              | 5 sessions |            |           |                                 |
| Stahl et al., 2019        | 130 aphasics         | Computer-assisted naming therapy and face-to-face communicative-pragmatic therapy | Yes | Anode: L M1 | 1 mA, 20 min | Yes       | Yes, at 6 months and 12 months | improvement in communicative ability |
|                          |                      |                                   |              |              | Two daily sessions over three consecutive weeks |            |           |                                 |
| Vila-Nova et al., 2019    | 12 (5 non-fluent, 5 fluent, 2 transcortical not defined) | Articulatory accuracy, syllable repetition, and word production | Yes, only for articulatory accuracy | Anode: L IFG | 1 mA, 20 min | No        | Yes, at 1 week and 4 months | improvement in articulatory accuracy |
|                          |                      |                                   |              |              | 5 sessions |            |           | qualitative follow up           |
| Authors | Number of Aphasics | Task(s) | Sham? | Anode/ Cathode | Stimulation Parameters | Outcome(s) | Notes |
|---------|-------------------|---------|-------|----------------|------------------------|------------|-------|
| Branscheidt et al., 2018 | 16 (6 non-fluent, 5 fluent, 5 mixed) | Lexical decision task | Yes | Anode: L MI | 2 mA, 20 min, 1 session | No | No improvement of accuracy in lexical decision, especially for action words |
| Silva et al., 2018 | 14 non-fluent | Naming task | Yes, only at Boston test (mean time for correct responses with strategy) | Cathode: R IFG | 2 mA, 20 min, 5 sessions | No | Yes, at 4 weeks only improvement in Boston test performance |
| Fridriksson et al., 2018 | 74 (43 non-fluent, 31 fluent) | Computerized behavioral treatment of anomia | Yes | Anode: L Temporal cortex | 1 mA, 20 min, 15 sessions | Yes | Yes, at 6 months improvement in anomia |
| Fridriksson et al., 2018 | 74 aphasics | Computerized picture-word matching task | Yes | Anode: L Temporal cortex | 1 mA, 20 min, 15 sessions | Yes | Yes, at 4 weeks and 24 weeks improvement in naming |
| Spielmann et al., 2018 | 13 aphasics | Word finding Therapy | Yes | Anode: L IFG or L ST | 1 mA, 20 min, 3 sessions | No | No improvement in word finding |
| Marangolo et al., 2018 | 12 non-fluent | Verb naming and verb generation | Yes, only for verb generation | Cathode: R cerebellar cortex | 2 mA, 20 min, 5 sessions | No | Yes, at 1 week improvement in verb generation |
| Pestalozzi et al., 2018 | 14 (10 non-fluent, 4 fluent) | Picture naming, phonemic fluency task, and repetition task | Yes | Anode: L DLPFC | 1 mA, 20 min, 1 session | No | No improvement in high-frequency word fluency |
| Woodhead et al., 2018 | 21 aphasics with central alexia | iReadMore training | Yes | Anode: L IFG | 2 mA, 20 min, 5 sessions | Yes | Yes, at 3 months facilitation in reading ability |
| Darkow et al., 2017 | 16 mild aphasics | Noun picture naming | No | Anode: L MI | 1 mA, 20 min, 1 session | Not investigated | No differences between real and sham condition |
| Study (Year, Reference) | Participants | Intervention Type | Improvement | Anode/Cathode | Current | Initial | Final | Improvement Notes |
|------------------------|--------------|-------------------|-------------|---------------|---------|---------|-------|-------------------|
| Santos et al., 2017    | 13 non-fluent | Picture naming    | No          | Anode: L IFG  | 2 mA, 20 min | 1 session | No    | No improvement in picture naming |
| Marangolo et al., 2017 | 14 aphasics   | Verb and noun naming | Yes         | Anode and Cathode: 10th thoracic vertebra | 2 mA, 20 min | 5 sessions | Not investigated | Yes, at 1 week improvement in verb naming after anodal stimulation |
| Norise et al., 2017    | 9 non-fluent  | Noun picture naming based on constraint-induced language therapy (CILT) | Yes         | Anode/ Cathode: L IFG Anodal/ Cathode: R IFG | 2 mA, for 20 min | 10 sessions | No    | Yes, at 2 weeks and 2 months improvement in speech fluency |
| Marangolo et al., 2016 | 9 non-fluent  | Repetition         | Yes         | Bihemispheric Anode: L IFG Cathode: R IFG | 2 mA, 20 min | 15 sessions | Yes   | Yes, at 1 week improvement in speech articulation |
| Meinzer et al., 2016   | 26 (15 non-fluent, 11 fluent) | Computer-assisted naming treatment | Yes         | Anode: L M1 Two daily treatment for 8 sessions | 1 mA, 20 min for | Not investigated | Yes   | Yes, at 6 months improvement in naming |
| Campana et al., 2015   | 20 non-fluent | Conversational therapy | Yes         | Anode: L IFG  | 2 mA, 20 min | 10 sessions | Not investigated | No improvement in picture description, noun and verb naming |
| Cipollari et al., 2015  | 6 non-fluent  | MIT                | Yes         | Anode: R IFG  | 2 mA, 20 min | 15 sessions | Yes   | Yes, at 1 week improvement in repetition accuracy for words and |
| Study | Group Size | Treatment |Yes | Anode/Cathode | TDCS Parameters | Sessions | Improvement |
|-------|------------|-----------|----|---------------|-----------------|----------|-------------|
| de Aguiar et al., 2015 | 9 (3 fluent, 6 non fluent) | Verb treatment “ACTION” | Yes | Bihemispheric | 1 mA, 20 min, 10 sessions | Yes | No | Improvement in verb production |
| Richardson et al., 2015 | 8 non-fluent | Computerized noun naming | Yes | Individualized determination of electrode placement by fMRI | 1 mA, 20 min, 22 sessions spread out in 5 weeks | No | Yes, at 1 week | Improvement in naming accuracy after HD-tDCS and CS-tDCS |
| Shah-Basak et al., 2015 | 12 non-fluent | Picture naming | Yes | Anode: L/R DLPFC, Cathode: L/R DLPFC | 2 mA, 20 min, 10 sessions | Yes | Yes, at 2 weeks and 2 months | Improvement in naming |
| Marangolo et al., 2014a | 7 non-fluent | Conversational therapy | Yes | Bihemispheric | 2 mA, 20 min, 10 sessions | Yes | Yes, at 1 week | Improvement in picture description, noun and verb naming |
| Marangolo et al., 2014b | 8 non-fluent | Conversational therapy | Yes | Anode: L IFG or L ST | 1 mA, 20 min, 10 sessions | Yes | No | Improvement in cohesive elements (pronouns, ellipses, word repetitions, conjunctions) after a-tDCS over LIFG |
| Study authors, Year | Participants | Tasks | Repetition | Anode/Cathode | Current and Duration | Improvement | Comments |
|---------------------|--------------|-------|------------|---------------|---------------------|-------------|----------|
| Vestito et al., 2014 [162] | 3 (2 non-fluent aphasics, 1 fluent anomic) | Noun and Verb picture naming | Yes | Anode: L IFG | 1.5 mA, 20 min (10 sessions) | Yes | Yes, at 6 weeks | Improvement in naming |
| Fiori et al., 2013 [21] | 7 non-fluent | Noun and Verb picture naming | Yes | Anode: L IFG or L ST or sham | 1 mA, 20 min (5 sessions) | Yes | Yes, at 1 week and 4 weeks | A-tDCS over L IFG improved verb naming; A-tDCS over L ST improved noun naming |
| Lee et al., 2013 [163] | 11 (6 non-fluent and 5 fluent) | Picture naming, reading short paragraphs | Yes | Single Anode: L IFG or Bihemispheric: Anode: L IFG Cathode: R IFG | 2 mA, 30 min (1 session) | Not investigated | No | Improvement in naming accuracy after bihemispheric and single tDCS. |
| Marangolo et al., 2013 a [25] | 12 non-fluent | Repetition | Yes | Bihemispheric: Anode: L IFG Cathode: R IFG | 1 mA, 20 min (5 sessions) | Yes | Yes at 1 week | Improvement in speech articulation |
| Marangolo et al., 2013 b [28] | 12 non-fluent | Conversational therapy | Yes | Anode: L IFG, L ST | 1 mA, 20 min (10 sessions) | Yes | Yes at 4 weeks | Improvement in informative speech, content units, verbs, and sentences |
| Marangolo et al., 2013 c [23] | 8 non-fluent | Picture naming | Yes | Anodal: L IFG or L ST | 1 mA, 20 min (5 sessions) | Not reported | Yes at 4 weeks | Improvement in verb naming after A-tDCS over the LIFG |
| Flöel et al., 2011 [164] | 12 (9 non-fluent and 3 fluent) | Computerized picture naming | Yes | Anode vs Cathode over R TP cortex; | 1 mA, 20 min (3 sessions) | No | Yes at 2 weeks | Improvement in picture naming |
| Study                  | Patient Summary | Task Type               | Auditory Feedback | Anode Location | Parameters | Motor Feedback | Outcome | Follow-up Duration | Result                  |
|-----------------------|-----------------|-------------------------|-------------------|----------------|------------|----------------|---------|-------------------|-------------------------|
| Fridriksson et al., 2011 [165] | 8 fluent        | Computerized picture naming | Yes               | Anode: L posterior cortex (individualized determination of fMRI) | 1mA, 20min  | No             | Yes, at 3 weeks | improvement in picture naming |
| Fiori et al., 2011 [22]  | 3 non-fluent     | Noun picture naming     | Yes               | Anode: L ST    | 1 mA, 20 min | Not reported   | Yes, at 3 weeks | improvement in picture naming |
| Kang et al., 2011 [166]  | 10 (8 non-fluent and 2 fluent) | Noun picture naming     | Yes               | Cathode: R IFG | 2 mA, 20 min | No             | No                  | improvement in picture naming |
| Marangolo et al., 2011 [24] | 3 non-fluent     | Repetition               | Yes               | Anode: L IFG   | 1 mA, 20 min | Yes            | Yes, at 1 week and at 2 months | improvement in speech accuracy and fluency |
| Vines et al., 2011 [167]  | 6 non-fluent     | MIT                      | Yes               | Anode: R IFG   | 1.2 mA, 20 min | Yes           | No                  | improvement in speech fluency      |
| Baker et al., 2010 [168]  | 10 (6 fluent and 4 non-fluent) | Computerized picture naming | Yes               | Anode: L F    | 1 mA, 20 min | Yes            | Yes, at 1 week | improvement in picture naming |
Similar to stroke motor function parameters, in tDCS studies, the electrode placement aims to restore the interhemispheric unbalance between the residual left language areas and the right hemispheric ones [169,170]. Thus, two broad approaches have been usually adopted: facilitation of activity in lesioned or perilesional areas through anodal stimulation [19-24,27,28,30,145-147,149,150,152-155,157,158,161-163,165,168] or inhibition of the intact right hemisphere to diminish abnormal transcallosal inhibition through cathodal stimulation [20,144,148,151,157,164,166]. Together with these two approaches, more recently, dual stimulation has been proposed in which the left and right hemisphere are simultaneously targeted with anodal and cathodal stimulation, respectively, to enhance activity into the left perilesional cortex [25,26,29,142]. Indeed, a very recent modeling study by Galletta et al. [171] which compared the most used electrode montages in tDCS aphasia studies, has concluded that dual stimulation exerts the highest electric field magnitude over the left perilesional areas. Thus, if our aim is to boost the recovery process into the left perilesional areas because, according to the literature, we believe that language recovery takes anyway place into the left hemisphere [172] through dual stimulation we can obtain this effect.

Studies also included a mix of different types of aphasia’s classification (reporting either the patients’ scores or classifying their symptoms and/or considering their speech fluency) contributing to their extreme heterogeneity [126]. The classical modular approach has been most often adopted, thus, positioning the active electrode either over the left Broca’s area [19,21,23-30,142,146,153,155,157,162,163,168], the left Wernicke’s area [19,21-23,28,30,149,150,164,165] or the right homologues [20,144,148,157,159,164,166,167]. Indeed, most of the research has proved that anodal stimulation over these areas combined with language therapy increases different aspects of language. Indeed, the Broca’s area is a crucial part of the language network involved in different aspect of language processing [173-175] and it also plays an important role in the recovery of units with high communicative value (i.e. content units) [28,30].

More specifically, a significant improvement has been shown in noun naming after anodal tDCS over the left frontal gyrus [27,29,157,162,163,168] the left temporal gyrus [21-23,149,150,165] or the right homologues [148,157,164,166]. Some other studies have targeted the left inferior frontal gyrus in order to improve verb naming [21,23,27-29,160], speech fluency [27-30], repetition [24-26,146] and reading [153]. A couple of reports [159,167] has also investigated whether melodic intonation therapy (MIT) combined with anodal stimulation over the right inferior frontal gyrus would increase articulatory difficulties in post-stroke aphasia. Both studies showed positive results with a greater improvement in syllables, words, and sentences repetition after the active condition [159,167].

More recent studies, overcoming the classical approach which considers the language faculty mostly represented into the Broca and Wernicke’s area, have investigated the impact of tDCS over different brain regions, and, in particular, over the motor regions [145,147,154,158]. In the study by Meinzer et al. [158], anodal tDCS was delivered twice daily for two weeks over the left motor cortex combined with a computer-assisted naming therapy. After the treatment, an increase in naming accuracy was found both for trained and untrained items which persisted at six months follow-up [158]. Another study has targeted the cerebellum resulting in an improvement in verb generation after cathodal DCS [151]. Two very recent studies have stimulated the spinal cord with the idea that enhancing activity into the sensorimotor network would improve words made up of sensorimotor properties, such as action verbs, which was the case [143,156].

Finally, two studies have targeted the dorsolateral prefrontal cortex [152,20] in order to investigate the role of executive functions on lexical-access. Pestalozzi et al. [152] combined left
dorsolateral prefrontal DCS with picture naming, verbal fluency, and word repetition tasks for two sessions. After the treatment, improvements in phonemic verbal fluency and picture naming were found, but only for very high-frequency words.

As reported in Table 3, the studies were not homogeneous on the number of sessions included varying from one [147,152,155,154,163] to five [21-25,142-144,146,148,151,153,156,165,166,168] to fifteen sessions [26,149,150,159]. While, for current intensity there was a substantial agreement to use 1mA [19,21-25,28,30,144-146,149,150,152,154,158,160,161,164,165,168] to 2 mA [20,26,27,29,142-144,147,148,151,153,155-157,159,163,166] Unfortunately, almost half of the reported studies did not include follow-up sessions [19,27,30,142,143,147,152,154,155,156,163,166,167] and, in the remaining studies, tDCS effects were measured up to 1-4 weeks after the treatment [20,21-23,25,26,28,29,144,146,148,150,151,156,157,159,161,162,164,165,168] but see [20,24,145,149,153,157,158]. Anyway, beyond this variability, the literature agrees on some aspects which might assure the long-term maintenance of stimulation efficacy. Long term effects are more easily obtained stimulating the subjects for several consecutive days [20-26,28,29,143-146,148-151,153,156-159,161,162,165,168]. Indeed, the hypothesis underlying multiple session paradigms is that short-lasting effects from a single session will accumulate with repeated sessions and eventually lead to a permanent improvement in the treated function [18] and/or on untrained materials [158]. It has also been suggested that higher current intensity (i.e. 2 mA) brings greater benefits than lower (i.e. 1 mA) [144]. Fiori et al. [144] highlighted that the systematic determination of stimulation intensity appears to be crucial for obtaining relevant effects. The authors found a significant improvement in verb naming only after cathodal high definition (HD)-tDCS at 2 mA compared to 1 mA.

One important point on which there is a total agreement is that tDCS must be delivered with concomitant language treatment [18,126]. Indeed, the rationale of the treatment is to potentiate the training [18].

Since anomia is the most common symptom in aphasia, most crossover studies focused on word recovery by combining tDCS with naming task, from noun treatment [20-23,149,154-158,161-166,168] to verb treatment [21,23,143,144,151,156,160,162]. tDCS has also been combined with repetition task [24-26,146], Melodic Intonation Therapy [159,167], and conversational therapy in order to enhance speech fluency [27-30,142,145].

In summary, although the results of these studies look very promising, it is worth noting that most of the studies have used a treatment approach (i.e. computerized matching, picture naming [20-23,150,152,154,155,157,162-164,166] which has not always been considered effective in the literature [12]. However, these approaches have been combined with tDCS because they offer a highly constrained replicable treatment method, possibly aimed at promoting repetition and intensity of the treatment, which are both aspects known to promote neuroplasticity [176]. Only very few studies have considered combining tDCS with evidence-based treatment [25,29,30,159,160,167]. Indeed, it is possible that pairing noninvasive brain stimulation with appropriate cognitive tasks and behavioral therapies may increase the “behavioral resolution” of the stimulation procedures. A final missed point was the lack of outcome measures for quantifying the improvement in functional communication. Indeed, one of the major challenges in aphasia rehabilitation is to find the persistence of gains in language and generalization to functional communication outcomes after the intervention [12].
4.1 Conclusions

In conclusion, although several aspects need to be clarified, there are a series of advantages that make tDCS suitable to be combined with aphasia treatment. tDCS is cost-effective, very well tolerated with low adverse effects, easy-to-use, thus, it can be administered easily in a variety of settings, as during language therapy [127,177]. Moreover, the low spatial and temporal resolution which does not allow for specifically targeting a particular language area [178-182] might result in a further advantage. Indeed, in our opinion, the diffusion of current inside a damaged system (i.e. the left hemisphere), if it exerts its influence also far away from the targeted area, it may not be entirely negative since it might simultaneously affect several undamaged areas resulting in greatest language recovery.

5. General conclusion

In this review, we have provided an overview of the most innovative approaches to post-stroke aphasia, which may overcome some limitations of traditional treatments. Indeed, as pointed out in the Introduction, there is a general agreement that treatment intensity is the most important predictor for treatment effectiveness [12]. However, for several reasons, it is not always possible to guarantee an intensive treatment for all patients [183]. A clear advantage of the above proposed approaches is that they might reinforce the effects of conventional therapies, thus, ensuring an adequate intensity of the treatment [88,107,4].

Apart from this, an interesting aspect of those techniques is that they all overcome the traditional view of language representation considering the language network much larger distributed throughout the brain than previously suggested by the classical approach [37,109,118,123,143,151,152,156,158]. Within this view, the language system closely interacts with other systems (e.g. the motor regions), thus, different part of the brain, if stimulated, might take part in language recovery. Indeed, the pharmacological approach aims to rebalance the neurotransmitter activity starting from the assumption that the same neurotransmitter might subserv different functions. Therefore, the action of the drugs will not be circumscribed into specific regions. It is likely that aphasic deficits, and probably other cognitive post-stroke deficits, partly result from damage to specific neurotransmission systems [36]. For example, it has already been suggested that damage to the cholinergic system may interfere with the processing of incoming verbal stimuli and favor the emergence of perseverations, omissions, and semantic errors in aphasia [73,184].

As previously pointed out, also the use of VR highlights the role of brain motor areas in language processing by demonstrating that activation of premotor and motor areas can influence the processing of words semantically related to actions. Accordingly, the use of tDCS has been recently extended over areas, different from the classical language ones, such as the motor regions [143,147,151,156,158].

Thus, we believe that these innovative approaches might result really promising for the future since, considering the language function more largely distributed over the brain, would allow us to potentiate language outcomes by referring to other systems. Indeed, given the wide variability of cortical lesions among aphasic patients, it is not always easy to localize through non-invasive brain
stimulation techniques, such as transcranial direct current stimulation (tDCS), the optimal stimulation cortical sites. This points to the urgency of considering other vicarious systems, functionally connected to the brain, that, when stimulated, contribute to the recovery of language. Unfortunately, due to the lack of a sufficient number of studies for each reported approach, we cannot reach a firm conclusion on its effectiveness. We urgently need to promote large clinical randomized trials in order to understand which is the best approach and, more importantly, which patients are likely to benefit.

**Author Contributions:** C.P., A.Q., F.P.: methodology, data curation, writing-original draft preparation; PM: Conceptualization, supervision, writing-review, and editing.

All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

[1] Basso, A.; Forbes, M.; Boller, F. Rehabilitation of aphasia. In *Handbook of Clinical Neurology*, 2013.

[2] Rohde, A.; Worrall, L.; Le Dorze, G. Systematic review of the quality of clinical guidelines for aphasia in stroke management. *J. Eval. Clin. Pract.* 2013, 19, 994-1003. doi:10.1111/jep.12023

[3] Basso, A. Aphasia Therapy. In *Oxford University Press*, 2005.

[4] Marangolo, P.; Caltagirone, C. Options to enhance recovery from aphasia by means of non-invasive brain stimulation and action observation therapy. *Expert Rev Neurother.* 2014, 14, 75-91. doi:10.1586/14737175.2014.864555

[5] Franzén-Dahlin, A.; Karlsson, M.R.; Mejhert, M.; Laska, A.C. Quality of life in chronic disease: a comparison between patients with heart failure and patients with aphasia after stroke. *J Clin Nurs.* 2010, 19, 1855-1860. doi:10.1111/j.1365-2702.2010.03219.x

[6] Fama, M.E.; Turkeltaub, P.E. Treatment of poststroke aphasia: current practice and new directions. *Semin Neurol.* 2014, 34, 504-513. doi:10.1055/s-0034-1396004

[7] Taub, E.; Usnawte, G.; Elbert, T. New treatments in neurorehabilitation founded on basic research. *Nat Rev Neurosci.* 2002, 3, 228-236. doi:10.1038/nrn754

[8] Elbert, T.; Rockstroh, B.; Bulach, D.; Meinzer, M.; Taub, E. Die Fortentwicklung der Neurorehabilitation auf verhaltensneurowissenschaftlicher Grundlage. Beispiel Constraint-induced-Therapie [New developments in stroke rehabilitation based on behavioral and neuroscientific principles: constraint-induced therapy]. *Nervenarzt* 2003, 74, 334-342. doi:10.1007/s00115-003-1498-1

[9] Elbert, T.; Sterr, A.; Rockstroh, B.; Pantev, C.; Müller, M.M.; Taub, E. Expansion of the tonotopic area in the auditory cortex of the blind. *J Neurosci.* 2002, 22, 9941-9944. doi:10.1523/JNEUROSCI.22-22-09941.2002

[10] Bhogal, S.K.; Teasell, R.; Speechley, M. Intensity of aphasia therapy, impact on recovery. *Stroke* 2003, 34, 987-993. doi:10.1161/01.STR.0000062343.64383.

[11] Hilarri, K.; Cruico, M.; Sorin-Peters, R.; Worrall, L. Quality of Life in Aphasia: State of the Art. *Folia Phoniatr Logop.* 2015, 67, 114-118. doi:10.1159/000440997

[12] Brady, M.C.; Kelly, H.; Godwin, J.; Enderby, P.; Campbell, P. Speech and language therapy for
aphasia following stroke. *Cochrane Database Syst Rev*. **2016**, 6, CD000425. doi:10.1002/14651858.

[13] Lazar, R.M.; Minzer, B.; Antoniello, D.; Festa, J.R.; Krakauer, J.W.; Marshall, R.S. Improvement in aphasia scores after stroke is well predicted by initial severity. *Stroke* **2010**, 41, 1485-1488. doi:10.1161/STROKEAHA.109.577338

[14] Bucur, M.; Papagno, C. Are transcranial brain stimulation effects long-lasting in post-stroke aphasia? A comparative systematic review and meta-analysis on naming performance. *Neurosci Biobehav Rev*. **2019**, 10, 264-289. doi:10.1016/j.neubiorev.2019.04.019

[15] Floel, A.; Cohen, L.G. Recovery of function in humans: cortical stimulation and pharmacological treatments after stroke. *Neurobiol Dis*. **2010**, 37, 243-251. doi:10.1016/j.nbd.2009.05.027

[16] Morosan, P.; Schleicher, A.; Amunts, K.; Zilles, K. Multimodal architectonic mapping of human superior temporal gyrus. *Anat Embryol (Berl)*. **2005**, 210, 401-406. doi:10.1007/s00429-005-0029-1

[17] Filgel, A.; Cohen, L.G. Recovery of function in humans: cortical stimulation and pharmacological treatments after stroke. *Neurobiol Dis*. **2010**, 37, 243-251. doi:10.1016/j.nbd.2009.05.027

[18] Marangolo, P. The potential effects of transcranial direct current stimulation (tDCS) on language functioning: Combining neuromodulation and behavioral intervention in aphasia. *Neurosci Lett*. **2020**, 719, 133329. doi:10.1016/j.neulet.2017.12.057

[19] Spielmann, K.; van de Sandt-Koenderman, W.M.; Heijenbrok-Kal, M.H.; Ribbers GM. Comparison of two configurations of transcranial direct current stimulation for aphasia treatment. *J Rehabil Med*. **2018**, 50, 527-533. doi:10.2340/16501977-2338

[20] Shah-Basak, P.P.; Norise, C.; Garcia, G.; Torres, J.; Faseytian, O.; Hamilton, R.H. Individualized treatment with transcranial direct current stimulation in patients with chronic non-fluent aphasia due to stroke. *Front Hum Neurosci*. **2015**, 9, 201. doi:10.3389/fnhum.2015.00201

[21] Fiori, V.; Cipollari, S.; Di Paola, M.; Razzano, C.; Caltagirone, C.; Marangolo, P. tDCS stimulation segregates words in the brain: evidence from aphasia. *Front Hum Neurosci*. **2013**, 7, 269. doi:10.3389/fnhum.2013.00269

[22] Fiori, V.; Coccia, M.; Marinelli, C.V.; Vecchi, V.; Bonifazi, S.; Ceravolo, M.G.; Provinciali, L.; Tomaiuolo, F.; Marangolo, P. Transcranial direct current stimulation improves word retrieval in healthy and nonfluent aphasic subjects. *J Cogn Neurosci*. **2011**, 23, 2309-2323. doi:10.1162/jocn.2010.21579

[23] Marangolo, P.; Fiori, V.; Caltagirone, C.; Marini, A. How Conversational Therapy influences language recovery in chronic non-fluent aphasia. *Neuropsychol Rehabil*. **2013**, 23, 715-731. doi:10.1080/09602011.2013.804847

[24] Marangolo, P.; Marinelli, C.V.; Bonifazi, S.; Ceravolo, M.G., Provinciali, L., Tomaiuolo, F. Electrical stimulation over the left inferior frontal gyrus (IFG) determines long-term effects in the recovery of speech apraxia in three chronic aphasics. *Behav Brain Res*. **2011**, 225, 498-504. doi:10.1016/j.bbr.2011.08.008

[25] Marangolo, P.; Fiori, V.; Cipollari, S.; Campana, S.; Razzano, C.; Di Paola, M.; Koch, G.; Caltagirone, C. Bihemispheric stimulation over left and right inferior frontal region enhances recovery from apraxia of speech in chronic aphasia. *Eur J Neurosci*. **2013**, 38, 3370-3377. doi:10.1111/ejn.12332

[26] Campana, S.; Caltagirone, C.; Marangolo, P. Combining Voxel-based Lesion-symptom Mapping

Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 9 December 2020 doi:10.20944/preprints202012.0238.v1
(VLSM) With A-tDCS Language Treatment: Predicting Outcome of Recovery in Nonfluent Chronic Aphasia. *Brain Stimul.* 2015;8,769-776. doi:10.1016/j.brs.2015.01.413

[28] Marangolo, P.; Fiori, V.; Calpagnano, M.A.; Campana, S.; Razzano, C.; Caltagirone, C.; Marini, A. tDCS over the left inferior frontal cortex improves speech production in aphasia. *Front Hum Neurosci.* 2013;7,539. doi:10.3389/fnhum.2013.00539

[29] Marangolo, P.; Fiori, V.; Gelfo, F.; Shofany, J.; Razzano, C.; Caltagirone, C.; Angelucci, F. Bihemispheric tDCS enhances language recovery but does not alter BDNF levels in chronic aphasic patients. *Restor Neurol Neurosci.* 2014;32,367-379. doi:10.3233/RNN-130323

[30] Marangolo, P.; Fiori, V.; Campana, S.; Calpagnano, M. A.; Razzano, C.; Caltagirone, C.; Marini, A. Something to talk about: enhancement of linguistic cohesion through tdCS in chronic non fluent aphasia. *Neuropsychologia* 2014;53,246-256. doi:10.1016/j.neuropsychologia.2013.12.003

[31] Hillis, A.E. Pharmacological, surgical, and neurovascular interventions to augment acute aphasia recovery. *Am J Phys Med Rehabil.* 2007, 86, 426-34. doi: 10.1097/PHM.0b013e31805ba094

[32] Prabhakaran, S.; Ruff I.; Bernstein, R.A. Acute stroke intervention: a systematic review. *JAMA* 2015, 313, 1451-62. doi: 10.1001/jama.2015.3058

[33] Carrera, E.; Tononi, G. Diaschisis: past, present, future. *Brain* 2014;137, 2408-2422. doi:10.1093/brain/awu101

[34] Zeiler, S.R.; Krakauer, J.W. The interaction between training and plasticity in the poststroke brain. *Curr Opin Neurol.* 2013;26, 609-616. doi:10.1097/WCO.000000000000025

[35] Kesser, Z.; Francisco, G.E. Neuropharmacology of Poststroke Motor and Speech Recovery. *Phys Med Rehabil Clin N Am.* 2015;26, 671-89. doi: 10.1016/j.pmr.2015.06.009

[36] Berthier, M.L.; Pulvermüller, F. Neuroscience insights improve neurorehabilitation of poststroke aphasia. *Nat Rev Neurol.* 2011, 7, 86-97. doi: 10.1038/nrneurol.2010.201

[37] Berthier, M.L.; Pulvermüller, F.; Dávila, G.; Casares, N.G.; Gutiérrez, A. Drug therapy of post-stroke aphasia: a review of current evidence. *Neuropsychol Rev.* 2011, 21, 30-17. doi: 10.1007/s11065-011-9177-7

[38] Güngör, L.; Terzi, M.; Onar, M.K. Does long term use of piracetam improve speech disturbances due to ischemic cerebrovascular diseases? *Brain Lang.* 2011, 117, 23-7. doi: 10.1016/j.bandl.2010.11.003

[39] Kessler, J.; Thiel, A.; Karbe, H.; Heiss, W.D. Piracetam improves activated blood flow and facilitates rehabilitation of poststroke aphasic patients. *Stroke* 2000, 31, 2112-6. doi:10.1161/01.str.31.9.2112

[40] Huber, W.; Willmes, K.; Poeck, K.; Van Vleymen, B.; Deberdt, W. Piracetam as an adjuvant to language therapy for aphasia: a randomized double-blind placebo-controlled pilot study. *Arch Phys Med Rehabil.* 1997, 78, 245-50. doi: 10.1016/s0003-9993(97)90028-9

[41] Enderby, P.; Broeckx, J.; Hospers, W.; Schildermans, F.; Deberdt, W. Effect of piracetam on recovery and rehabilitation after stroke: a double-blind, placebo-controlled study. *Clin Neuropharmacol.* 1994, 17, 320-31. doi: 10.1097/00002826-199408000-00003

[42] Dávila, G.; Moyano, M.P.; Edelkraut, L.; Moreno-Campos, L.; Berthier, M.L.; Torres-Prioris, M.J.; López-Barroso, D. Pharmacotherapy of Traumatic Childhood Aphasia: Beneficial Effects of Donepezil Alone and Combined With Intensive Naming Therapy. *Front Pharmacol.* 2020, 11, 1144. doi: 10.3389/fphar.2020.01144.
[44] Woodhead, Z.V.; Crinion, J.; Teki, S.; Penny, W.; Price, C.J.; Leff, A.P. Auditory training changes temporal lobe connectivity in 'Wernicke's aphasia': a randomised trial. J Neurol Neurosurg Psychiatry 2017, 88, 586-594. doi: 10.1136/jnnp-2016-314621

[45] Yoon, S.Y.; Kim, J.K; An, Y.S.; Kim, Y.W. Effect of Donepezil on Wernicke Aphasia After Bilateral Middle Cerebral Artery Infarction: Subtraction Analysis of Brain F-18 Fluorodeoxyglucose Positron Emission Tomographic Images. Clin Neuropharmacol. 2015, 38, 147-50. doi: 10.1097/WNF.0000000000000089

[46] Berthier, M.L.; Green, C.; Higueras, C.; Fernández, I.; Hinojosa, J.; Martín, M.C. A randomized, placebo-controlled study of donepezil in poststroke aphasia. Neurology 2006, 67, 1687-9. doi: 10.1212/01.wnl.0000242626.69666.e2

[47] Berthier, M.L.; Hinojosa, J.; Martín Mdel, C.; Fernández, I. Open-label study of donepezil in chronic poststroke aphasia. Neurology 2003, 60, 1218-9. doi: 10.1212/01.wnl.0000055871.82308.41

[48] Hong, J.M.; Shin, D.H.; Lim, T.S.; Lee, J.S.; Huh, K. Galantamine administration in chronic post-stroke aphasia. J Neurol Neurosurg Psychiatry 2012, 83, 675-80. doi: 10.1136/jnnp-2012-302268

[49] Barbancho, M.A.; Berthier, M.L.; Navas-Sánchez, P.; Dávila, G.; Green-Heredia, C.; García-Alberca, J.M.; Ruiz-Cruces, R.; López-González, M.V.; Dawid-Milner, M.S.; Pulvermüller, F.; Lara, J.P. Bilateral brain reorganization with memantine and constraint-induced aphasia therapy in chronic post-stroke aphasia: An ERP study. Brain Lang. 2015, 145-146, 1-10. doi: 10.1016/j.bandl.2015.04.003.

[50] Raymer, A.M.; Bandy, D.; Adair, J.C.; Schwartz, R.L.; Williamson, D.J.; Gonzalez Rothi, L.J.; Heilman, K.M. Effects of bromocriptine in a patient with crossed nonfluent aphasia: a case report. Arch Phys Med Rehabil. 2001, 82, 139-44. doi: 10.1053/apmr.2001.18056

[51] Gold, M.; VanDam, D.; Silliman, E.R. An open-label trial of bromocriptine in nonfluent aphasia: a qualitative analysis of word storage and retrieval. Brain Lang. 2000, 74, 141-56. doi:10.1006/brln.2000.2332

[52] Bragoni, M.; Altieri, M.; Di Piero, V.; Padovani, A.; Mostardini, C.; Lenzi, G.L. Bromocriptine and speech therapy in non-fluent chronic aphasia after stroke. Neurol Sci. 2000, 21, 19-22. doi:10.1007/s100720070114
Sabe, L.; Salvarezza, F.; Garcia Cuerva, A.; Leiguarda, R.; Starkstein, S. A randomized, double-blind, placebo-controlled study of bromocriptine in nonfluent aphasia. *Neurology* 1995, 45, 2272-4. doi: 10.1212/wnl.45.12.2272

Gupta, S.R.; Mlcoch, A.G. Bromocriptine treatment of nonfluent aphasia. *Arch Phys Med Rehabil.* 1992, 73, 373-6. doi: 10.1016/0003-9993(92)90012-I

Keser, Z.; Dehgan, M.W.; Shadran, S.; Yozbatiran, N.; Maher, L.M.; Francisco, G.E. Combined Dextroamphetamine and Transcranial Direct Current Stimulation in Poststroke Aphasia. *Am J Phys Med Rehabil.* 2017, 96, S141-S145. doi:10.1097/PHM.0000000000000780

Spiegel, D.R.; Alexander, G. A case of nonfluent aphasia treated successfully with speech therapy and adjunctive mixed amphetamine salts. *J Neuropsychiatry Clin Neurosci.* 2011, 23, E24. doi:10.1176/jnp.23.1.jnpe24

Whiting, E.; Chenery, H.J.; Chalk, J.; Copland, D.A. Dexamphetamine boosts naming treatment effects in chronic aphasia. *J Int Neuropsychol Soc.* 2007, 13, 972-979. doi:10.1017/S1355617707071317

McNeil, M. R.; Doyle, P. J.; Spencer, K. A.; Jackson Goda, A.; Flores, D.; Small, S. L. A double-blind, placebo-controlled study of pharmacological and behavioural treatment of lexical-semantic deficits in aphasia. * Aphasiology* 1997 11, 385-400. doi:10.1080/026870703970829479

Walker-Batson, D.; Curtis, S.; Natarajan, R.; Ford, J.; Dronkers, N.; Salmeron, E.; Lai, J.; Unwin, D. H. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. *Stroke* 2001, 32, 2093-2098. doi:10.1161/hs0901.095720

Walker-Batson, D.; Devous, D.; Sr. Curtis, S. S.; Unwin, D. H.; Greenlee, R G. Response to Amphetamine to Facilitate Recovery from Aphasia Subsequent to Stroke. 1991 Pro-Ed

Winblad, B. Piracetam: a review of pharmacological properties and clinical uses. *CNS Drug Rev.* 2005, 11, 169-82. doi: 10.1111/j.1527-3458.2005.tb00268.x

Berthier, M.L. Poststroke aphasia: epidemiology, pathophysiology, and treatment. *Drugs Aging* 2005, 22, 163-82. doi: 10.2165/00002512-200522020-00006

Kandel, E. R.; Schwartz, J. H.; Jessel, T. M.; Siegelbaum, S. A.; Hudspeth, A.J. Principi di neuroscienze, 4th ed. (Italian); Casa Editrice Ambrosiana: Rozzano (MI), Italy, 2015.

Mesulam, M.; Siddique, T.; Cohen, B. Cholinergic denervation in a pure multi-infarct state: observations on Cadasil. *Neurology* 2003, 60, 1183–1185.

Husain, M.; Mehta, M.A. Cognitive enhancement by drugs in health and disease. *Trends Cogn Sci.* 2011, 15, 28-36. doi:10.1016/j.tics.2010.11.002

Sarter, M.; Hasselmo, M. E.; Bruno, J. P.; Givens, B. Unraveling the attentional functions of cortical cholinergic inputs: Interactions between signal-driven and cognitive modulation of signal detection. *Brain Research Reviews* 2005, 48, 98–111

Tan, C.C.; Yu, J.T.; Wang, H.F.; Tan, M.S.; Meng, X.F.; Wang, C.; Jiang, T.; Zhu, X.C.; Tan, L. Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer’s disease: a systematic review and meta-analysis. *J Alzheimers Dis.* 2014, 41, 615-31. doi: 10.3233/JAD-132690

Moriguchi, S.; Marszalec, W.; Zhao, X.; Yeh, J.Z.; Narahashi, T. Mechanism of action of...
galantamine on N-methyl-D-aspartate receptors in rat cortical neurons. *J Pharmacol Exp Ther.* **2004**, *310*, 933-42. doi: 10.1124/jpet.104.067603

[76] Johnson, J.W.; Kotermanski, S.E. Mechanism of action of memantine. *Curr Opin Pharmacol.* **2006**, *6*, 61-7. doi: 10.1016/j.coph.2005.09.007

[77] Parsons, C.G.; Stöffler, A.; Danysh, W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. *Neuropharmacology* **2007**, *53*, 699-723. doi: 10.1016/j.neuropharm.2007.07.013

[78] Acler, M.; Manganotti, P. Role, indications and controversies of levodopa administration in chronic stroke patients. *Eur J Phys Rehabil Med.* **2013**, *49*, 243-9.

[79] Kauer, J.A.; Malenka, R.C.; Nicoll, R.A. NMDA application potentiates synaptic transmission in the hippocampus. *Nature* **1988**, *334*, 354-2.

[80] Lovinger, D.M., Tyler, E. Synaptic transmission and modulation in the neostriatum. *Int Rev Neurobiol* **1996**, *39*, 77-111.

[81] Bliss, T.V.; Goddard, G.V.; Riives, M. Reduction of long-term potentiation in the dentate gyrus of the rat following selective depletion of monoamine. *J Physiol* **1983**, *334*, 475-91.

[82] Knecht, S.; Breitenstein, C.; Bushuven, S.; Wailke, S.; Kamping, S.; Fliöl, A.; Zwitserlood, P.; Ringelstein, E.B. Levodopa: faster and better word learning in normal humans. *Ann Neurol.* **2004**, *56*, 20-6. doi: 10.1002/ana.20125

[83] Albert, K.A.; Hemmings, H.C. Jr; Adamo, A.I.; Potkin, S. G.; Akbarian, S.; Sandman, C. A.; Cotman, C. W.; Bunney, W. E., Jr, Greengard, P. Evidence for decreased DARPP-32 in the prefrontal cortex of patients with schizophrenia. *Arch Gen Psychiatry* **2002**, *59*, 705–712. doi:10.1001/archpsyc.59.8.705

[84] Kandel, E.R. The molecular biology of memory storage: a dialogue between genes and synapses. *Science* **2001**, 294, 1030–1038.

[85] Granon, S.; Passetti, F.; Thomas, K.L.; Dalley, J. W.; Everitt, B. J.; Robbins, T. W. Enhanced and impaired attentional performance after infusion of D1 dopaminergic receptor agents into rat prefrontal cortex. *J Neurosci* **2000**, *20*, 1208–1215. doi:10.1523/JNEUROSCI.20-03-01208.2000

[86] Williams, G.V.; Goldman-Rakic, P.S. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. *Nature* **1995**, *376*, 572–575.

[87] Lieberman, A.N.; Goldstein, M. Bromocriptine in Parkinson’s disease. *Pharmacol Rev.* **1985**, *37*, 217-27.

[88] de Boissezon, X.; Peran, P.; de Boysson, C.; Démonet, J.F. Pharmacotherapy of aphasia: myth or reality? *Brain Lang.* **2007**, *102*, 114-25. doi: 10.1016/j.bandl.2006.07.004

[89] Pinel, J. P. J.; Barnes, S. J. *Biopsychology*, 10th ed.; Pearson: London, UK, 2018.

[90] Sitte, H. H.; Freissmuth, M. Amphetamines, new psychoactive drugs and the monoamine transporter cycle. *Trends in pharmacological sciences* **2015**, *36*, 41–50. doi:10.1016/j.tips.2014.11.006

[91] Robertson, S.D.; Matthies, H.J.; Galli, A. A closer look at amphetamine induced reverse transport and trafficking of the dopamine and norepinephrine transporters. *Mol Neurobiol.* **2009**, *39*, 73–80.

[92] Westfall, T.C.; Westfall, D.P. Adrenergic agonists and antagonists. In *Goodman & Gilman's The Pharmacological Basis of Therapeutics*, 11th ed.; Brunton, L.L.; Lazo, J.S.; Parker, K.L. Eds.; The McGraw-Hill Companies: New York, 2006.

[93] Globe ATS Assessment. Amphetamines and ecstasy. United Nations Office on Drugs and Crime, 2011.

[94] Parrott, A. C. Human psychobiology of MDMA or ‘Ecstasy’: an overview of 25 years of empirical
research. *Human psychopharmacology* 2013, 28, 289–307. doi:10.1002/hup.2318

[95] Marshall, J. F.; O’Dell, S. J. Methamphetamine influences on brain and behavior: unsafe at any speed? *Trends in neurosciences* 2012, 35, 536–545.

[96] Lake, C. R.; Quirk, R. S. CNS stimulants and the look-alike drugs. The Psychiatric clinics of North America 1984, 7, 689–701.

[97] Sinita, E.; Coghill, D. The use of stimulant medications for non-core aspects of ADHD and in other disorders. *Neuropharmacology* 2014, 87, 161–172.

[98] Sprigg, N.; Bath, P.M. Speeding stroke recovery? A systematic review of amphetamine after stroke. *J Neurol Sci.* 2009, 285, 3-9. doi: 10.1016/j.jns.2009.04.040

[99] Khokar, A.; Kirmani, J.F.; Xavier, A.R.; Qureshi, A.I. The therapeutic potential of amphetamines in Post-stroke recovery. *Curr. Med. Chem. - Central Nerv. Syst. Agent* 2003, 3, 49-55.

[100] Szelenberger, R.; Kostka, J.; Saluk-Bijak, J.; Miller, E. Pharmacological Interventions and Rehabilitation Approach for Enhancing Brain Self-repair and Stroke Recovery. *Curr Neuropsychol*. 2020, 18, 51-64. doi: 10.2174/1570159X17666190726104139

[101] Choi, M.J.; Kim, H.; Nah, H.W.; Kang, D.W. Digital Therapeutics: Emerging New Therapy for Neurologic Deficits after Stroke. *J Stroke*. 2019, 21, 242-258. doi: 10.5853/jos.2019.01963

[102] Palmer, R.; Dimairo, M.; Cooper, C.; Enderby, P.; Brady, M.; Bowen, A.; Latimer, N.; Julious, S.; Cross, E.; Alshreef, A.; Harrison, M.; Bradley, E.; Witts, H.; Chater, T. Self-managed, computerised speech and language therapy for patients with chronic aphasia post-stroke compared with usual care or attention control (Big CACTUS): a multicentre, single-blinded, randomised controlled trial. *Lancet Neurol.* 2019,18,821-833. doi:10.1016/S1474-4422(19)30192-9

[103] Lavoie, M.; Routhier, S.; Légaré, A.; Macoir, J. Treatment of verb anomia in aphasia: efficacy of self-administered therapy using a smart tablet. *Neurocase* 2016, 22, 109-18. doi: 10.1080/13554794.2015.1051055

[104] Lavoie, M.; Bier, N.; Macoir, J. Efficacy of a self-administered treatment using a smart tablet to improve functional vocabulary in post-stroke aphasia: a case-series study. *Int J Lang Commun Disord.* 2019, 54, 249-264. doi: 10.1111/1460-6984.12439

[105] Kurland, J.; Wilkins, A.R; Stokes, P. iPractice: piloting the effectiveness of a tablet-based home practice program in aphasia treatment. *Semin Speech Lang*. 2014, 35, 51-63. doi: 10.1055/s-0033-1362991

[106] Hoover, E.L.; Carney, A. Integrating the iPad into an intensive, comprehensive aphasia program. *Semin Speech Lang*. 2014, 35, 25-37. doi: 10.1055/s-0033-1362990

[107] Repetto, C.; Paolillo, M. P.; Tuena, C.; Bellinzona, F.; Riva, G. Innovative technology-based interventions in aphasia rehabilitation: a systematic review. *Aphasiology* 2020, 1-24. doi:10.1080/02687038.2020.1819957

[108] Tieri, G.; Morone, G.; Paolucci, S.; Iosa, M. Virtual reality in cognitive and motor rehabilitation: facts, fiction and fallacies. *Expert Rev Med Devices*. 2018, 15, 107-117. doi:10.1080/17434440.2018.1425613.

[109] Grechuta, K.; Rubio Ballester, B.; Espín Munne, R.; Usabiaga Bernal, T.; Molina Hervás, B.; Mohr, B.; Pulvermüller, F.; San Segundo, R.; Verschure, P. Augmented Dyadic Therapy Boosts Recovery of Language Function in Patients With Nonfluent Aphasia. *Stroke* 2019, 50, 1270-1274. doi: 10.1161/STROKEAHA.118.023729

[110] Snell, S.; Martin, N.; Keshner, E. A. Engagement with a virtual clinician encourages gesture usage in speakers with aphasia. In 2017 International Conference on Virtual Rehabilitation (ICVR). 2017, 6, 20–25.

[111] Zhang, Y.; Chen, P.; Lin, X.; Wan, G.; Xie, C.; Yu, X. Clinical research on therapeutic effect of
virtual reality technology on Broca Aphasia patients. In 2017 2nd International Conference on Information Technology (INCIIT), 2017.

[112] Marshall, J.; Booth, T.; Devane, N.; Galliers, J.; Greenwood, H.; Hilari, K.; Talbot, R.; Wilson, S.; Woolf, C. Evaluating the Benefits of Aphasia Intervention Delivered in Virtual Reality: Results of a Quasi-Randomised Study. *PLoS One* 2016, 11, e0160381. doi: 10.1371/journal.pone.0160381

[113] Marangolo, P.; Pisano, F. Conversational Therapy in Aphasia: From Behavioral Intervention to Neurormodulation. *Semin Speech Lang.* 2020, 41, 61-70. doi: 10.1055/s-0039-3399500.

[114] Savage, M. C.; Donovan, N. J. Comparing linguistic complexity and efficiency in conversations from stimulation and conversation therapy in aphasia. *Int J Lang Commun Disord.* 2017, 52, 21-29. doi:10.1111/1460-6984.12252

[115] Walker, T.; Thomson, J.; Watt, I. Displays and claims of understanding in conversation by people with aphasia. *Aphasiology* 2015, 30(6), 750–764.

[116] Thompson, C.K.; Choy, J.J.; Holland, A.; Cole, R. Sentactics®: Computer-Automated Treatment of Underlying Forms. *Aphasiology* 2010, 24, 1242-1266. doi: 10.1080/02687030903474255

[117] Cherney, L.R.; van Vuuren, S. Telerehabilitation, virtual therapists, and acquired neurologic speech and language disorders. *Semin Speech Lang.* 2012, 33, 243-57. doi: 10.1055/s-0032-1320044

[118] Giachero, A.; Calati, M.; Pia, L.; La Vista, L.; Molo, M.; Rugiero, C.; Fornaro, C.; Marangolo, P. Conversational Therapy through Semi-Immersive Virtual Reality Environments for Language Recovery and Psychological Well-Being in Post Stroke Aphasia. *Behav Neurol.* 2020, 2020, 2846046. doi: 10.1155/2020/2846046

[119] Marshall, J.; Devane, N.; Talbot, R.; Caute, A.; Cruice, M.; Hilari, K.; MacKenzie, G.; Maguire, K.; Patel, A.; Roper, A.; Wilson, S. A randomized trial of social support group intervention for people with aphasia: A Novel application of virtual reality. *PLoS One* 2020, 15, e0239715. doi:10.1371/journal.pone.0239715.

[120] Maresca, G.; Maggio, M.G.; Latella, D.; Cannavò, A.; De Cola, M.C.; Portaro, S.; Stagnitti, M.C.; Silvestri, G.; Torrissi, M.; Bramanti, A.; De Luca, R.; Calabrò, R.S. Toward Improving Poststroke Aphasia: A Pilot Study on the Growing Use of Telerehabilitation for the Continuity of Care. *J Stroke Cerebrovasc Dis.* 2019, 28, 104303. doi: 10.1016/j.jstrokecerebrovasdis.2019.104303

[121] Marshall, J.; Devane, N.; Edmonds, L.; Talbot, R.; Wilson, S.; Woolf, C.; Zwart, N. Delivering word retrieval therapies for people with aphasia in a virtual communication environment, *Aphasiology* 2018, 32, 1054-1074. doi:10.1080/02687038.2018.1488237

[122] Carragher, M.; Talbot, R.; Devane, N.; Rose, M.; Marshall, J. Delivering storytelling intervention in the virtual world of EVA Park, *Aphasiology* 2018, 32, 37-39. doi: 10.1080/02687038.2018.1484880

[123] Grechuta, K.; Bellaster, B.R.; Munne, R.E.; Bernal, T.U.; Hervas, B.M.; Segundo, R.S.; Verschure P. F. M.J. The effects of silent visuomotor cueing on word retrieval in Broca's aphasies: A pilot study. IEEE Int Conf Rehabil Robot. 2017, 2017, 193-199. doi: 10.1109/ICORR.2017.8009245

[124] Pulvermüller, F.; Huss, M.; Kherif, F.; Moscoso del Prado Martin, F.; Hauk, O.; Shtyrov, Y. Motor cortex maps articulatory features of speech sounds. *Proc Natl Acad Sci U S A* 2006, 103, 7865-70. doi: 10.1073/pnas.0509989103

[125] Marangolo, P.; Bonifazi, S.; Tomaiuolo, F.; Craighero, L.; Coccia, M.; Altoè, G.; Provinciali, L.; Cantagallo, A. Improving language without words: first evidence from aphasia. *Neuropsychologia* 2010, 48, 3824-33. doi: 10.1016/j.neuropsychologia.2010.09.025

[126] Fregni, F.; El-Hagrassy, M.M.; Pacheco-Barrios, K.; Carvalho, S.; Leite, J.; Simis, M.; Brunelin, J.; Nakamura-Palacios, E.M.; Marangolo, P.; Venkatasubramanian, G.; San-Juan, D.; Caumo, W.; Bikson,
Evidence-based guidelines and secondary meta-analysis for the use of transcranial direct current stimulation (tDCS) in neurological and psychiatric disorders. *Int J Neuropsychopharmacol.* 2020, pyaa051. doi:10.1093/ijnp/pyaa051

Lefaucheur, J.P.; Antal, A.; Ayache, S.S.; Benninger, D.H.; Brunelin, J.; Cogianianian, F.; Cotelli, M.; De Ridder, D.; Ferrucci, R.; Langguth, B.; Marangolo, P.; Mylius, V.; Nitsche, M.A.; Padberg, F.; Palm, U.; Poulet, E.; Priori, A.; Rossi, S.; Sheckmann, M.; Vanneste, U.; Garcia-Larrea, L.; Paulus, W. Evidence-based guidelines on the therapeutic use of transcranial direct current stimulation (tDCS). *Clin Neurophysiol.* 2017, 128, 56-92. doi:10.1016/j.clinph.2016.10.087

Monte-Silva, K.; Kuo, M.F.; Hessenthaler, S.; Fresnoza, S.; Liebetanz, D.; Paulus, W.; Nitsche, M.A. Induction of late LTP-like plasticity in the human motor cortex by repeated non-invasive brain stimulation. *Brain Stimul.* 2013, 6, 424-432. doi:10.1016/j.brs.2012.04.011

Nitsche, M.A.; Paulus, W. Transcranial direct current stimulation—update 2011. *Restor Neurol Neurosci.* 2011, 29, 463-492. doi:10.3233/RNN-2011-0618

Nitsche, M.A.; Doemkes, S.; Karaköse, T.; Antal, A.; Liebetanz, D.; Lang, N.; Tergau, F.; Paulus, W. Shaping the effects of transcranial direct current stimulation of the human motor cortex. *J Neurophysiol.* 2007, 97, 3109-3117. doi:10.1152/jn.01312.2006

Spielmann, K.; van de Sandt-Koenderman, W.M.E.; Heijenbrok-Kal, M.H.; Ribbers, G.M. Transcranial Direct Current Stimulation Does Not Improve Language Outcome in Subacute Poststroke Aphasia. *Stroke* 2018, 49, 1018-1020. doi:10.1161/STROKEAHA.117.020197

Wu, D.; Wang, J.; Yuan, Y. Effects of transcranial direct current stimulation on naming and cortical excitability in stroke patients with aphasia. *Neurosci Lett.* 2015, 589, 115-120. doi:10.1016/j.neulet.2015.01.045

Polanowska, K.E.; Leśniak, M.; Seniów, J.B.; Członkowska, A. No effects of anodal transcranial direct stimulation on language abilities in early rehabilitation of post-stroke aphasic patients. *Neurol Neurochir Pol.* 2013, 47, 414-422. doi:10.5114/nnp.2013.38221

Polanowska, K.E.; Leśniak, M.M.; Seniów, J.B.; Czepiel, W.; Członkowska, A. Anodal transcranial direct current stimulation in early rehabilitation of patients with post-stroke non-fluent aphasia: a randomized, double-blind, sham-controlled pilot study. *Restor Neurol Neurosci.* 2013;31, 761-771. doi:10.3233/RNN-130333

You, D.S.; Kim, D.Y.; Chun, M.H.; Jung, S.E.; Park, S.J. Cathodal transcranial direct current stimulation of the right Wernicke’s area improves comprehension in subacute stroke patients. *Brain Lang.* 2011, 119,1-5. doi:10.1016/j.bandl.2011.05.002

Buchwald, A.; Khosa, N.; Rimikis, S.; Duncan, E.S. Behavioral and neurological effects of tDCS on speech motor recovery: A single-subject intervention study. *Brain Lang.* 2020, 210,104849. doi:10.1016/j.bandl.2020.104849

Sebastian, R.; Saxena, S.; Tsapkini, K.; Faria, A. V.; Long, C.; Wright, A.; Davis, C.; Tippett, D. C.; Mourtoukoutas, A. P.; Bikson, M.; Celnik, P.; Hillis, A. E. Cerebellar tDCS: A Novel Approach to Augment Language Treatment Post-stroke. *Front Hum Neurosci.* 2017, 10,695. doi:10.3389/fnhum.2016.00695

Costa, V.; Giglia, G.; Brighina, F.; Indovino S., Fierro B. Ipsilesional and contralesional regions participate in the improvement of poststroke aphasia: a transcranial direct current stimulation study. *Neurocase* 2015, 21,479-488. doi:10.1080/13554794.2014.927508

Galletta, E.E.; Vogel-Eyny, A. Translational treatment of aphasia combining neuromodulation and behavioral intervention for lexical retrieval: implications from a single case study. *Front Hum
Manenti, R.; Petesi, M.; Brambilla, M.; Rosini, S.; Miozzo, A.; Padovani, A.; Miniussi, C.; Cotelli, M. Efficacy of semantic-phonological treatment combined with tDCS for verb retrieval in a patient with aphasia. *Neurocase* 2015, 21, 109-119. doi:10.1080/13554794.2013.873062

Cherney, L.R.; Babbitt, E.M.; Hurwitz, R.; Rogers, L. M.; Stinear, J.; Wang, X.; Harvey, R. L.; Parrish, T. Transcranial direct current stimulation and aphasia: the case of mr. C. *Top Stroke Rehabil.* 2013, 20, 5-21. doi:10.1310/tsr2001-5

Guillouët, E.; Cogné, M.; Saverot, E.; Roche, N.; Pradat-Diehl, P.; Weill-Chounlamountry, A.; Ramel, V.; Taratte, C.; Lachasse, A. G.; Haulot, J. A.; Vaugier, I.; Barbot, F.; Azouvi, P.; Charveriat, S. Impact of Combined Transcranial Direct Current Stimulation and Speech-language Therapy on Spontaneous Speech in Aphasia: A Randomized Controlled Double-blind Study. *J Int Neuropsychol Soc.* 2020, 26, 7-18. doi:10.1017/S1355617719001036

Marangolo, P.; Fiori, V.; Caltagirone, C.; Incoccia, C.; Gili, T. Stairways to the brain: Transcutaneous spinal direct current stimulation (tsDCS) modulates a cerebellar-cortical network enhancing verb recovery. *Brain Res.* 2020, 1727, 146564. doi:10.1016/j.brainres.2019.146564

Fiori, V.; Nitsche, M.A.; Cucuzza, G.; Caltagirone, C.; Marangolo, P. High-Definition Transcranial Direct Current Stimulation Improves Verb Recovery in Aphasic Patients Depending on Current Intensity. *Neuroscience.* 2019, 406, 159-166. doi:10.1016/j.neuroscience.2019.03.010

Stahl, B.; Darkow, R.; von Podewils, V.; Meinzer, M.; Grittner, U.; Reinhold, T.; Grewe, T.; Breitenstein, C.; Flöel, A. Transcranial Direct Current Stimulation to Enhance Training Effectiveness in Chronic Post-Stroke Aphasia: A Randomized Controlled Trial Protocol. *Front Neurol.* 2019, 10, 1089. doi:10.3389/fneur.2019.01089

Vila-Nova, C.; Lucena, P.H.; Lucena, R.; Armani-Franceschi, G.; Campbell, F.Q. Effect of Anodal tDCS on Articulatory Accuracy, Word Production, and Syllable Repetition in Subjects with Aphasia: A Crossover, Double-Blinded, Sham-Controlled Trial. *Neurol Ther.* 2019, 8, 411-424. doi:10.1007/s40120-019-00149-4

Branscheidt, M.; Hoppe, J.; Zwitserlood, P.; Liuzzi, G. tDCS over the motor cortex improves lexical retrieval of action words in poststroke aphasia. *J Neurophysiol.* 2018, 119, 621-630. doi:10.1152/jn.00285.2017

Silva, F.R.D.; Mac-Kay, A.P.M.G.; Chao, J.C.; Santos, M.D.D.; Gagliadi, R.J. Transcranial direct current stimulation: a study on naming performance in aphasic individuals. Estimulação transcraniana por corrente continua: estudo sobre respostas em tarefas de nomeação em afásicos. *Codos* 2018, 30, e20170242. doi:10.1590/2317-1782/20182017242

Fridriksson, J.; Rorden, C.; Elm, J.; Sen, S.; George, M.S.; Bonilha, L. Transcranial Direct Current Stimulationion vs Sham to Treat Aphasia After Stroke: A Randomized Clinical Trial. *JAMA Neurol.* 2018, 75, 1470-1476. doi:10.1001/jamaneurol.2018.2287

Fridriksson, J.; Elm, J.; Stark, B.C.; Basilakos, A.; Rorden, C.; Sen, S.; George, M. S.; Gottfried, M.; Bonilha, L. BDNF genotype and tDCS interaction in aphasia treatment. *Brain Stimul.* 2018, 11, 1276-1281. doi:10.1016/j.brs.2018.08.009

Marangolo, P.; Fiori, V.; Caltagirone, C.; Pisano, F.; Priori, A. Transcranial Cerebellar Direct Current Stimulation Enhances Verb Generation but Not Verb Naming in Poststroke Aphasia. *J Cogn Neurosci.* 2018, 30, 188-199. doi:10.1162/jocn_a_01201

Pestalozzi, M. I.; Di Pietro, M.; Martins Gaytanidis, C.; Spierer, L.; Schnider, A.; Chouiter, L.; Colombo, F.; Annoni, J. M.; Jost, L. B. Effects of Prefrontal Transcranial Direct Current Stimulation on...
Lexical Access in Chronic Poststroke Aphasia. *Neuropsychol Neural Repair*. 2018, 32, 913-923. doi:10.1177/1545968318801551

[153] Woodhead, Z.; Kerry, S. J.; Aguilar, O. M.; Ong, Y. H.; Hogan, J. S.; Pappa, K.; Leff, A. P.; Crinion, J. T. Randomized trial of iReadMore word reading training and brain stimulation in central alexia. *Brain* 2018, 141, 2127-2141. doi:10.1093/brainawy138

[154] Darkow, R.; Martin, A.; Würtz, A.; Flöel, A.; Meinerz, M. Transcranial direct current stimulation effects on neural processing in post-stroke aphasia. *Hum Brain Mapp.* 2017, 38, 1518-1531. doi:10.1002/hbm.23469

[155] Santos, M.D.D.; Cavenaghi, V.B.; Mac-Kay, A.P.M.G.; Serafim, V.; Venturi, A.; Truong, D. Q.; Huang, Y.; Boggio, P. S.; Fregni, F.; Simis, M.; Bikson, M.; Gagliardi, R. J. Non-invasive brain stimulation and computational models in post-stroke aphasic patients: single session of transcranial magnetic stimulation and transcranial direct current stimulation. A randomized clinical trial. *Sao Paulo Med J.* 2017; 135, 475-480. doi:10.1590/1516-3180.2016.0194060617

[156] Marangolo, P.; Fiori, V.; Shofany, J.; Gili, T.; Caltagirone, C.; Cucuzza, G.; Priori, A. Transcutaneous Spinal Direct Current Stimulation in Post-Stroke Aphasia. *Front Neurol.* 2017, 8, 400. doi:10.3389/fneur.2017.00400

[157] Norise, C.; Sacchetti, D.; Hamilton, R. Transcranial Direct Current Stimulation in Post-stroke Chronic Aphasia: The Impact of Baseline Severity and Task Specificity in a Pilot Sample. *Front Hum Neurosci.* 2017, 11, 260. doi:10.3389/fnhum.2017.00260

[158] Meinerz, M.; Darkow, R.; Lindenberg, R.; Flöel, A. Electrical stimulation of the motor cortex enhances treatment outcome in post-stroke aphasia. *Brain*. 2016, 139, 1152-1163. doi:10.1093/brain/aww002

[159] Cipollari, S.; Veniero, D.; Razzano, C.; Caltagirone, C.; Koch, G.; Marangolo P. Combining TMS-EEG with transcranial direct current stimulation language treatment in aphasia. *Expert Rev Neurother.* 2015, 15, 833-845. doi:10.1586/14737175.2015.1049998

[160] de Aguiar, V.; Bastiaanse, R.; Capasso, R.; Gandolfi, M.; Smania, N.; Rossi, G.; Miceli, G. Can tDCS enhance item-specific effects and generalization after linguistically motivated aphasia therapy for verbs?. *Front Behav Neurosci.* 2015, 9, 190. doi:10.3389/fnbeh.2015.00190

[161] Richardson, J.; Datta, A.; Dmochowski J.; Parra, L.C.; Fridriksson, J. Feasibility of using high-definition transcranial direct current stimulation (HD-tDCS) to enhance treatment outcomes in persons with aphasia. *NeuroRehabilitation* 2015, 36, 115-126. doi:10.3233/NRE-141199

[162] Vestito, L.; Rosellini, S.; Mantero, M.; Bandini, F. Long-term effects of transcranial direct-current stimulation in chronic post-stroke aphasia: a pilot study. *Front Hum Neurosci.* 2014, 8, 785. doi:10.3389/fnhum.2014.00785

[163] Lee, S.Y.; Cheon, H.J.; Yoon, K.J.; Chang, W.H.; Kim, Y.H. Effects of dual transcranial direct current stimulation for aphasia in chronic stroke patients. *Ann Rehabil Med.* 2013, 37, 603-610. doi:10.5535/arm.2013.37.5.603

[164] Flöel, A.; Meinerz, M.; Kirstein, R.; Nijhof, S.; Deppe, M.; Knecht, S.; Breitenstein, C. Short-term anomia training and electrical brain stimulation. *Stroke* 2011, 42, 2065-2067. doi:10.1161/STROKEAHA.110.609032

[165] Fridriksson, J.; Richardson, J. D.; Baker, J. M.; Rorden, C. Transcranial direct current stimulation improves naming reaction time in fluent aphasia: a double-blind, sham-controlled study. *Stroke* 2011, 42, 819-821. doi:10.1161/STROKEAHA.110.600288

[166] Kang, E. K.; Kim, Y. K.; Sohn, H. M.; Cohen, L. G.; Paik, N. J. Improved picture naming in
aphasia patients treated with cathodal tDCS to inhibit the right Broca’s homologue area. *Restor Neurol Neurosci.* **2011**, *29*, 141-152. doi:10.3233/RNN-2011-0587

[167] Vines, B.W.; Norton, A.C.; Schlaug, G. Non-invasive brain stimulation enhances the effects of melodic intonation therapy. *Front Psychol.* **2011**, *2*, 230. doi:10.3389/fpsyg.2011.00230

[168] Baker, J.M.; Rorden, C.; Fridriksson, J. Using transcranial direct-current stimulation to treat stroke patients with aphasia. *Stroke* **2010**, *41*, 1229-1236. doi:10.1161/STROKEAHA.109.576785

[169] Murase, N.; Duque, J.; Mazzocchio, R.; Cohen, L.G. Influence of interhemispheric interactions on motor function in chronic stroke. *Ann Neurol.* **2004**, *55*, 400-409. doi:10.1002/ana.10848

[170] Belin, P.; Van Eechoudt, P.; Zilbovicius, M.; Remy, P.; François, C.; Guillaume, S.; Chain, F.; Rancurel, G.; Samson, Y. Recovery from nonfluent aphasia after melodic intonation therapy: a PET study. *Neurology* **1996**, *47*, 1504-1511. doi:10.1212/wnl.47.6.1504

[171] Galletta, E. E.; Cancelli, A.; Cottone, C.; Simonelli, I.; Tecchio, F.; Bikson, M.; bran, P. Use of Computational Modeling to Inform tDCS Electrode Montages for the Promotion of Language Recovery in Post-stroke Aphasia. *Brain Stimul.* **2015**, *8*, 1108-1115. doi:10.1016/j.brs.2015.06.018

[172] Nenert, R.; Allendorfer, J. B.; Martin, A. M.; Banks, C.; Vannest, J.; Holland, S. K.; Hart, K. W.; Lindsell, C. J.; Szaflarski, J. P. Longitudinal fMRI study of language recovery after a left hemispheric ischemic stroke. *Restor Neurol Neurosci.* **2018**, *36*, 359-385. doi:10.3233/RNN-170767

[173] Marini, A.; Urgesi, C. Please get to the point! A cortical correlate of linguistic informativeness. *J Cogn Neurosci.* **2012**, *24*, 2211-2222. doi:10.1162/jocn_a_00283

[174] Hagoort, P. On Broca, brain, and binding: a new framework. *Trends Cogn Sci.* **2005**, *9*, 416-423. doi:10.1016/j.tics.2005.07.004

[175] Gough, P.M.; Nobre, A.C.; Devlin, J.T. Dissociating linguistic processes in the left inferior frontal cortex with transcranial magnetic stimulation. *J Neurosci.* **2005**, *25*, 8010-8016. doi:10.1523/JNEUROSCI.2307-05.2005

[176] Kleim, J.A.; Jones, T.A. Principles of experience-dependent neural plasticity: implications for rehabilitation after brain damage. *J Speech Lang Hear Res.* **2008**, *51*, S225-S239. doi:10.1044/1092-4388(2008/018)

[177] Bikson, M.; Grossman, P.; Thomas, C.; Zannou, A. L.; Jiang, J.; Adnan, T.; Mourdoukoutas, A. P.; Kronberg, G.; Truong, D.; Boggio, P.; Brunoni, A. R.; Charvet, L.; Fregn, F.; Fritsch, B.; Gillick, B.; Hamilton, R. H.; Hampstead, B. M.; Jankord, R.; Kirton, A.; Knothova, H.; … Woods, A. J. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. *Brain Stimul.* **2016**, *9*, 641-661. doi:10.1016/j.brs.2016.06.004

[178] Marshall, J.; Atkinson, J.; Smulovitch, E.; Thacker, A.; Woll, B. Aphasia in a user of British Sign Language: Dissociation between sign and gesture. *Cogn Neuropsychol.* **2004**, *21*, 537-554. doi:10.1080/0269993042000249

[179] Ardolino, G.; Bossi, B.; Barbieri, S.; Priori, A. Non-synaptic mechanisms underlie the after-effects of cathodal transcutaneous direct current stimulation of the human brain. *J Physiol.* **2005**, *568*, 653-663. doi:10.1113/jphysiol.2005.088310

[180] Boros, K.; Poreisz, C.; Münchau, A.; Paulus, W.; Nitsche, M.A. Premotor transcranial direct current stimulation (tDCS) affects primary motor excitability in humans. *Eur J Neurosci.* **2008**, *27*, 1292-1300. doi:10.1111/j.1460-9568.2008.06090.x

[181] Lang, C.E.; Lohse, K.R.; Birkenmeier, R.L. Dose and timing in neurorehabilitation: prescribing motor therapy after stroke. *Curr Opin Neurol.* **2015**, *28*, 549-555. doi:10.1097/WCO.0000000000000256
[182] Kwon, Y. H.; Ko, M. H.; Ahn, S. H.; Kim, Y. H.; Song, J. C.; Lee, C. H.; Chang, M. C.; Jang, S. H. Primary motor cortex activation by transcranial direct current stimulation in the human brain. Neurosci Lett. 2008, 435, 56-59. doi:10.1016/j.neulet.2008.02.012

[183] Pierce, J. E.; O’Halloran, R.; Menahemi-Falkov, M.; Togher, L.; Rose, M. L. Comparing higher and lower weekly treatment intensity for chronic aphasia: A systematic review and meta-analysis. Neuropsychol Rehabil. 2020, 1, 25. doi:10.1080/09602011.2020.1768127

[184] Hasselmo, M.E.; McGaughy, J. High acetylcholine levels set circuit dynamics for attention and encoding and low acetylcholine levels set dynamics for consolidation. Prog Brain Res. 2004, 145, 207-231. doi:10.1016/S0079-6123(03)45015-2